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 Drug resistance to anti-cancer chemotherapy is a significant barrier to the 
treatment of leukemia patients. Many times, resistance results from molecular 
adaptation to drug exposure, such as genetic mutation of key enzymes, up-
regulation of pro-survival compensatory signaling pathways, and altered drug 
transport. In this dissertation, we describe two examples of molecular drug 
resistance in cell models of 1) Ara-C-resistant acute lymphoblastic leukemia (ALL) 
and 2) imatinib-resistant chronic myelogenous leukemia (CML). First, we determined 
that nucleoside transport is deficient in the Ara-C-resistant T-cell ALL CCRF-CEM 
cell line (Ara-C/8C) in comparison to drug-sensitive parental CCRF-CEM cells. 
Further study found a single point mutation in glycine residue 24 (G24) within 
equilibrative nucleoside transporter 1 (ENT1), a protein responsible for nucleoside 
uptake in these cells. Therefore, we tested the ability of G24A, G24R, and G24E 
ENT1 mutants to transport uridine and Ara-C and localize to the plasma membrane. 
Our data suggest that mutation of G24 disrupts ENT1 transport activity without 
altering localization; thus, expression of mutant ENT1 may confer Ara-C resistance 
in CCRF-CEM AraC/8C cells. In the second portion of the dissertation, we studied 
the role of Lyn tyrosine kinase (Lyn) in imatinib-resistant CML MYL-R cells. In 
 iii
comparison to drug-sensitive parental MYL cells, Lyn was hyper-active, and loss of 
Lyn activity sensitized cells to imatinib treatment. We determined that Lyn inhibited 
miR181 microRNA (miRNA) expression in MYL-R cells at the transcriptional level. In 
addition, we determined that miR181b targeted the 3’ UTR of Mcl-1, a pro-survival 
protein associated with drug-resistance, resulting in Mcl-1 degradation. Thus, we 
defined a molecular signaling axis by which Lyn may confer drug resistance in 
imatinib-resistant CML. We attempted to elucidate the mechanism of Lyn-dependent 
miR181 expression and found that 1) the transcription factors CREB and STAT5 do 
not regulate miR181a/b and 2) Lyn may regulate miR181c/d expression through 
modification of histone acetylation. These studies contribute to our knowledge of 
drug resistance mechanisms in leukemia and provide novel biomarkers for the 
identification of drug-resistant cancer. 
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1.1. Introduction to leukemia 
1.1.1. Overview of leukemia 
Leukemia is characterized by the unregulated growth of hematopoietic cells. 
In 2010, there were estimated to be approximately 43,000 new cases of leukemia 
with nearly 22,000 deaths expected to result from this disease [1]. The four major 
types of leukemia include, from the myeloid cell lineage, acute myelogenous 
leukemia (AML) and chronic myelogenous leukemia (CML) and, derived from the 
lymphoid cell lineage, acute lymphocytic leukemia (ALL) and chronic lymphocytic 
leukemia (CLL) (Fig. 1.1). Classification of leukemia as acute or chronic depends on 
the overall proliferation rate of the disease as well as the level of cellular 
differentiation. Acute leukemia is fast growing and requires immediate treatment; 
cells are typically immature and undifferentiated. In contrast, cells in chronic 
leukemia are more differentiated and slower growing and have enhanced survival in 
comparison to normal cells. Leukemia patients are less able to combat infection due 
to compromised immune function and typically succumb to secondary infections. 
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Figure 1.1. Hematopoiesis of blood-derived cells. Schematic depiction of normal 
human blood cell differentation. 
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1.1.2. Lymphoblastic leukemia 
1.1.2.1. CLL overview and standard of care 
Hematopoietic cells of the lymphoid cell lineage mature into B cells or T cells, 
depending on the site of maturation (bone marrow and thymus, respectively), and 
serve as integral components of the innate immune system. CLL is characterized by 
lymphocytosis, including the following criteria: 1) expression of B cell-associated 
antigens (CD19, CD20, and CD23); expression of the T cell-associated CD5 
antigen; and 3) low levels of surface membrane immunoglobin (Ig) [2]. This disease 
predominates in older individuals with a median age of diagnosis of 70 years [3]. In 
addition, CLL is the most common leukemia in Western society where it accounts for 
approximately 30% of all diagnosed leukemias [4]. Cytogenetic abnormalities have 
not been consistently associated with either the cause or pathogenesis of CLL, 
though some have been associated with prognosis. In particular, 11q and 17p 
deletions are associated with progressive disease and shorter survival [5, 6]. In 
addition, up-regulation of the Bcl-2 pro-survival protein often occurs in CLL [7]. 
Due to the heterogeneity of the disease, the prognosis of CLL patients is 
extremely variable. Correlation studies of variable region immunoglobin heavy 
chains (vHC) have determined that 30-40% of CLL patients express mutations or 
rearrangements of these genes [8]. Though patients with vHC mutations tend to 
have less malignant cancers, the appearance of mutation is independent of CLL 
clinical stage. Recently, research has focused on CD38 and Zap-70 as prognostic 
factors; patients who express both markers tend to have a poor prognosis [9]. 
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Whether the expression of these proteins is predictive of response to therapy is 
unknown. 
Traditionally, CLL has been treated with chlorambucil (Leukeran), a nitrogen 
mustard-alkylating agent; however low complete remission (CR) responses in 
patients have given way to treatment with antimetabolite agents or monoclonal 
antibodies. Treatment with purine analogs, such as fludarabine (Fludara), results in 
higher CR rates (20-40% vs. 10%) and longer disease-free survival [10]. 
Furthermore, the efficacy of fludarabine is improved upon combination with other 
agents. For example, the combination of fludarabine, cyclophosphamide 
(Cytoxan), and the monoclonal CD20 antibody rituximab (Rituxan) results in a 
superior response rate than fludarabine alone and longer patient survival [11].  
1.1.2.2. ALL overview and standard of care 
The majority of ALL is diagnosed in children, comprising approximately 30% 
of all childhood malignancies [12]. This disease is sub-divided into B-cell ALL (B-
ALL) and T-cell ALL (T-ALL) depending on the cell lineage affected, which is 
determined by the expression of lineage-specific CD antigens. Genetic 
underpinnings for these diseases are often stratified; however, common to both B-
ALL and T-ALL is rearrangement of the Ig and T-cell receptor (TCR) genes [13]. The 
presence of these and other genetic mutations, as well as the age of the patient, 
leukocyte count, and presence or absence of central nervous system or testicular 
leukemia involvement has a large impact on the treatment regimen. Of note, the 
presence of the Philadelphia chromosome (Ph+) (discussed in detail in Section 
1.1.3.1 CML Overview and Standard of Care) is found in approximately 15-20% of 
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all ALL cases; the incidence increases with age with approximately 3% of children 
and 25% of adult ALL cases Ph+ [14, 15]. This mutation gives rise to the BCR-Abl 
oncogene; thus, treatment with BCR-Abl-targeted inhibitors, such as imatinib 
(Gleevec), is appropriate. 
The overall survival is high (75-80%) for childhood ALL, whereas an overall 
survival rate of only 40-50% is typically obtained in adults with ALL [16, 17]. Ph+ 
patients have a poor prognosis and experience a low CR rate; however, the 
introduction of imatinib as a front-line treatment has dramatically improved the 5-
year CR rate (80-90%) [14]. Ph- ALL is first treated with short-term intensive 
chemotherapy consisting of antimetabolites (cytarabine (Ara-C; Cytosar-U), 
methotrexate (Trexall)), alkylating agents (cyclophosphamide), 
immunosuppressants (dexamethasone (Decadron), prednisone (Deltasone)), 
and/or cytotoxic agents (vincristine (Oncovin), anthracyclines) [18]. Specifically, 
treatment of adult ALL patients with the hyperfractionated cyclophosphamide, 
vincristine, doxorubicin (Adriamycin), and dexamethasone (Hyper-CVAD) regimen 
can obtain a CR rate >80% [19].  
1.1.3 Myelogenous leukemia 
1.1.3.1. CML overview and standard of care 
In contrast to ALL, CML is relatively rare in children (<5% of cases) and has a 
median age of onset between 55 and 60 years of age with nearly half of CML 
patients over the age of 60 [20]. The hallmark of CML is the presence of a 
translocation between chromosomes 9 and 22 (t(9;22)(q34;q11), which creates what 
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is known as the Philadelphia (Ph) chromosome. This mutation was first described by 
Peter Nowell in the mid-1960s and is found in approximately 95% of CML patients 
[21, 22]. This specific translocation gives rise to the BCR-Abl kinase, a fusion of part 
of the breakpoint cluster region (BCR) with the Abelson (Abl) tyrosine kinase. BCR-
Abl is the causative oncogene in Ph+ CML (reviewed in Section 1.3.2 BCR-Abl 
kinase). 
If untreated, CML progresses through three phases; in order of severity these 
are chronic, accelerated, and blast crisis. Individuals in chronic phase may be 
asymptomatic but have an elevated white blood cell (WBC) count (<15% 
myeloblasts); most patients first present in this stage. However, eventually the 
accelerated production of WBCs, including the increased presence of 
undifferentiated myeloblasts (>30%), occurs as patients transition through the 
accelerated phase into blast crisis. At this point, the production of normal blood cells 
and blood-clotting platelets is compromised, typically resulting in mortality due to 
anemia, infection, uncontrolled bleeding, or other complications. Treatment regimens 
depend on the phase of disease. A younger patient of reasonable health in the 
relatively indolent chronic phase typically undergoes allogeneic hematopoietic cell 
transplant (HCT) within the first year of diagnosis [23]. HCT may be an option for 
patients with advanced CML; however, the success of HCT treatment decreases 
with increasing disease severity. 
Traditionally, CML has been treated with antimetabolites (cytarabine), 
interferon, or hydroxyurea (Hydrea). These regimens result in a complete 
cytogenetic response (0% Ph+ cells in bone marrow) in approximately 30-35% of 
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patients; nearly 80% of these patients experienced disease-free survival 10 years 
after treatment [24, 25]. However, in 2001, the approval of imatinib, a BCR-Abl 
inhibitor, revolutionized the treatment of CML. Treatment with imatinib produces a 
major cytogenetic response in approximately 60% of patients and a complete 
hematologic response (blood platelet cell counts return to normal) in 95% of patients 
[26]. A study of 553 patients with chronic phase CML treated with continuous 
imatinib therapy found that the 5-year survival rate was approximately 89% [27]. 
These superior results have made imatinib the front-line treatment used to treat 
CML. More recently, second generation BCR-Abl inhibitors, such as nilotinib 
(Tasinga) and dasatinib (Sprycel), have been approved for treatment of newly 
diagnosed CML and CML patients resistant to imatinib [28-30]. 
1.1.3.2. AML overview and standard of care 
AML is the most common type of leukemia in adults with a median age of 
diagnosis between 65 and 75 years [12]. This disease has the lowest survival rate of 
any leukemia and many patients are non-responsive to treatment or relapse after 
initial therapy [31]. In contrast to CML, AML is a heterogeneous disease with a 
variety of cytogenetic and molecular alterations. Cytogenetic abnormalities occur in 
approximately 50-60% of newly diagnosed patients and some genetic 
rearrangements are indicative of poor prognosis [32]. A common molecular marker 
is the expression of mutant forms of FMS-like kinase 3 (FLT3). Constitutive 
activation of the FLT3 tyrosine kinase occurs after point mutation (D835) or gene 
translocation (FLT3-ITD); these mutations occur in approximately 20-30% of AML 
patients and are associated with a poor prognosis [33, 34]. 
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FLT3 plays a critical role in governing hematopoiesis and cellular growth. 
Expression of constitutively active FLT3 has transformative capacity in Ba/F3 B-cells 
[35]. In addition, FLT3-ITD expression in lymphoid and myeloid progenitor cells in a 
bone marrow transplant mouse model produced myeloproliferative disease [36]. 
Ligand-independent cell hyper-proliferation induced by FLT3-ITD is primarily 
mediated through RAS/MAPK and STAT5 activation [37]. 
The standard of care for treatment of AML includes a combination of 
anthracycline and cytarabine, sometimes with the addition of etoposide (Eposin), 
cladribine (Leustatin), and fludarabine. Inhibitors of FLT3, such as PKC412 
(midostaurin), are currently in clinical trials and have produced a favorable response 
when given alone or in combination with the standard of care [38, 39]. Though with 
only 20-40% of patients responding to initial therapy and nearly 50-70% of those 
patients experiencing relapse within 3 years, novel therapies for the treatment of 
AML are needed [40].  
1.2. ENTs and drug resistance 
1.2.1. ENT overview and functional aspects 
 Nucleosides are transported across cellular membranes by the equilibrative 
and concentrative nucleoside transporters (ENT and CNT, respectively). ENTs 
transport nucleoside substrates bidirectionally across membrane barriers down their 
concentration gradient, whereas CNTs concentrate substrates in a sodium-
dependent manner [41]. The studies herein focus on the regulation of ENT-
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dependent transport; therefore, the remainder of this introduction highlights our 
knowledge of ENT function.  
 In humans, the ENT family is composed of 4 members (ENT1-4), of which the 
function of ENT1 and ENT2 is best understood [42]. ENT1 has nearly ubiquitous 
tissue distribution and transports various purine and pyrimidine nucleosides, with the 
exception of uracil, in a Km range of 50 µM (adenosine) to 680 µM (cytidine) [43]. 
ENT2 is 49% identical (69% similar) to ENT1 and is found in a variety of tissues, 
though it is primarily expressed in skeletal muscle [44]. Immunohistochemical 
studies have shown ENT2 expression on the plasma membrane [42]. In addition, 
other studies suggest that ENT2 and/or ENT2 splice variants function as nuclear 
transporters [45, 46]. ENT2 transports a broad range of purine and pyrimidine 
nucleosides with the exception of cytidine and displays a lower affinity to these 
substrates in comparison to ENT1. In contrast to ENT1, ENT2 can also transport 
nucleobases, such as hypoxanthine [43, 47]. Of note, uridine is a permeant of both 
ENT1 and ENT2 with a Km of 260 µM and 250 µM, respectively [43].  
 Selective inhibitors can be used to delineate ENT1- and ENT2-mediated 
transport, as demonstrated by Ward et al. [43]. Nitrobenzylmercaptopurine riboside 
(NBMPR) is a purine analog and a potent inhibitor of ENT1 activity; its IC50 to 
inhibition of ENT1-mediated uridine transport is 0.4 +/- 0.1 nM, whereas inhibition of 
ENT2-mediated transport occurs at an IC50 of 2.8 +/- 0.3 µM, a nearly 10,000-fold 
difference in potency. Dipyridamole (Persantine) is a less selective inhibitor with a 
difference in IC50 for ENT1 and ENT2 of approximately 100-fold (5.0 +/- 0.9 nM vs. 
356 +/- 13 nM, respectively).  
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ENT1 contains 11 transmembrane (TM) α-helices with a cytosolic N-terminus 
and an extracellular C-terminus [48]. Based on glycosylation scanning mutagenesis, 
ENT1 is glycosylated on N48, which is located between TM1 and TM2; however, 
glycosylation is not essential for activity [49]. Using chimeric recombinant proteins of 
NBMPR-sensitive rat ENT1 and NBMPR-insensitive rat ENT2, it was determined 
that the binding domains for NBMPR reside within amino acids 100-231 
encompassing TM3-6 [50]. In addition, site-directed mutational analysis of ENT1 has 
uncovered additional residues outside this region that are important for NBMPR 
binding, including F334, N338, and L92 [51, 52]. 
 Because NBMPR is a direct competitor of nucleoside transport, many regions 
that are important for NBMPR binding are also contact points for nucleoside binding. 
For example, site-directed mutagenesis of human ENT1 expressed in S. cerevisiae 
demonstrated that G179 in TM5 was required for uridine transport and sensitivity to 
NBMPR [53]. In addition, this study suggested that G184 may partially determine 
targeting of the transporter to the plasma membrane [53]. G154 was also reported to 
be important for nucleoside transport and sensitivity to the inhibitors NBMPR, 
dipyridamole, and dilazep [54].  
Similar to NBMPR binding, studies suggest that amino acids in TM domains 
other than 3-6 may also be critical for the transport of nucleoside substrates. 
Specifically, M33 in TM1 and I429 in the TM11 of human ENT1 and ENT2 and C. 
elegans ENT1 were reported to be required for nucleoside transport and may 
contribute to the binding of dipyridamole [55]. A report by Paproski et al. 
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demonstrated that W29 within TM1 was important for inhibitor binding, and ENT1s 
containing mutations of W29 have altered nucleoside transport kinetics [56]. 
1.2.2. Regulation of ENT1 
 ENT expression and activity are regulated at both the transcriptional and 
post-translational levels. In addition, ENT1 transcription in cancer cells is 
coordinated with the cell cycle, with an approximate doubling of ENT1 content 
between the G1 and G2/M phases [57]. In response to lack of oxygen, ENT1 and 
ENT2 mRNA expression is decreased in a hypoxia inducible factor 1 (HIF1)-
dependent manner; this may provide a molecular mechanism to elevate extracellular 
adenosine, subsequently dilating blood vessels [58]. In addition, functional analysis 
of the mouse ENT1 promoter revealed regulation of gene expression by the MAZ 
and Sp-1 transcription factors [59]. Furthermore, research in our lab has uncovered 
a mechanism by which N-terminal c-Jun kinase (JNK) can regulate ENT expression 
through the activation of signaling transducer and activator of transcription 3/5 
(STAT3/5) proteins [60].  
 Of particular note, a recent study by Jin et al. demonstrated that ENT1 is 
regulated at the transcriptional level by FLT3 [61]. Cell lines that express 
constitutively activated FLT3-ITD down-regulated ENT1 expression and promoter 
activity and were resistant to cytarabine treatment. This regulation was dependent 
on HIF-1 and reversal of this phenotype was observed after treatment with the FLT3 
inhibitor PKC412 [61]. 
 Additionally, ENT activity may be regulated at the post-translational level. 
Previous studies have documented protein kinase C (PKC)-dependent enhancement 
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of ENT1, but not ENT2, activity in various cell lines [62-64]. Though PKC-dependent 
ENT1 phosphorylation has not been clearly demonstrated, PKC membrane 
localization is required for ENT1 modulation and bioinformatics analysis reveals 
potential consensus PKC phosphorylation sites within ENT1 [62, 65] (PROSITE 
Database, http://www.expasy.ch/prosite/). Furthermore, Coe et al. demonstrated that 
administration of PMA, an activator of PKC, increased the binding affinity between 
ENT1 and NBMPR without altering the number of NBMPR binding sites, suggesting 
a PKC-dependent protein modification that may induce a conformation change [63]. 
In addition to PKC, ENT1 may be positively regulated by casein kinase 2 (CK2) [66]. 
Treatment with the CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) or deletion 
of the CK2 consensus phosphorylation site in mouse ENT1 (S254) reduced 
nucleoside transport activity [66]. 
1.2.3. Resistance to nucleoside analog treatment 
1.2.3.1. Introduction to nucleoside analogs 
 In addition to natural nucleosides, ENTs transport nucleoside and nucleobase 
analogs, which are commonly used for the treatment of cancer, particularly 
leukemia. Once inside the cell, these compounds exert their cytotoxic effects 
primarily by incorporating into DNA during replication or DNA repair. For example, 
cytarabine, and gemcitabine (Gemzar) accumulate in cells in their triphosphate 
forms, Ara-CTP and dFdCTP, respectively, and compete with CTP for DNA 
incorporation [67, 68]. In addition, analogs can disrupt specific metabolic pathways 
to induce cell death. For instance, 5-fluorouracil (5-FU, Adrucil), a nucleobase 
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antimetabolite, competes with dUMP for thymidylate synthase, resulting in depletion 
of dTTP and inhibition of DNA replication [69]. Furthermore, the purine nucleoside 
analog fludarabine directly inhibits ribonucleotide reductase, depleting dNTP pools 
[70]. 
 Numerous nucleoside analogs are FDA-approved for the treatment of 
hematological malignancies. Cytarabine is given for induction and maintenance 
therapy of AML, from which a CR rate of 60-80% can be achieved [40]. Gemcitabine 
is an analog of cytarabine that is more commonly used against solid tumors, such as 
pancreatic cancer and metastatic bladder cancer [71, 72]. However, in combination 
with other agents, gemcitabine effectively treats lymphoid malignancies [73]. 
Fludarabine and the closely related purine nucleoside prodrug cladribine are used to 
treat low-grade lymphomas and CLL [74, 75]. The standard of care for leukemia and 
application of nucleoside analogs is reviewed in Section 1.1 Introduction to 
Leukemia. 
1.2.3.2. Nucleoside analog transport and resistance 
 Studies suggest that the transport of nucleoside analogs is necessary for, or 
at least greatly increases, the cytotoxic effects of these agents. Mackey et al. 
demonstrated that the IC50 value of gemcitabine-dependent inhibition of cell 
proliferation was 100-3000-fold higher in cells that lack nucleoside transport in 
comparison to cells that actively transport gemcitabine [76]. In a study of childhood 
AML, Hubeek et al. found an inverse correlation between ENT1 mRNA expression 
and sensitivity to cytarabine, such that low ENT1 levels were associated with 
cytarabine resistance [77]. ENT1 mRNA expression was also determined to be a 
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predictor of 5-FU resistance in pancreatic cancer and pre-treatment with NBMPR 
increases drug sensitivity [78]. Numerous other clinical and pre-clinical studies have 
determined a relationship between ENT1 abundance and chemosensitivity [79-87].  
 In addition, ENT dysfunction has been associated with resistance to 
nucleoside analogs [88]. Genetic mutation may result in non-functional ENTs or 
ENTs that have reduced activity. In a cytarabine-resistant cell line, Cai et al. 
described two independent mutations in ENT1 that resulted in a non-functional 
protein due to a shortened transcript and a transcript lacking exon 13, both of which 
were associated with increased drug resistance [89]. In addition, profiling of an 
ethnically diverse population uncovered ENT1 proteins with variations in the coding 
region; however, kinetic analysis of these proteins in yeast found no difference in 
transporter function [90]. Furthermore, single nucleotide polymorphisms (SNPs) in 
ENT genes may determine individual responsiveness to nucleoside analog 
treatment [91]. 
1.3. Kinase signaling in leukemia 
1.3.1. Overview of kinase function 
 Reversible phosphorylation was first uncovered by Ed Krebs and Ed Fischer 
during the mid-1950s [92]. Their discovery of cAMP-dependent protein kinase (PKA) 
created a new field of research for the discovery and characterization of kinases. 
These proteins catalyze the transfer of a negatively charged phosphate (PO4) group 
from ATP to specific serine, threonine, and tyrosine residues on protein, oftentimes 
resulting in an alteration in protein conformation and catalytic activity. Currently, 
there are 518 known kinases in the human genome with approximately 90 kinases 
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that phosphorylate tyrosine residues, whereas the large majority of kinases (385) 
phosphorylate serine and threonine residues [93]. These events are integral to 
molecular signaling and kinases are involved in every aspect of cellular regulation, 
including cell growth, proliferation, and apoptosis.  
Importantly, kinase dysregulation is a hallmark of many cancers. The non-
receptor tyrosine kinase Src was the first cancer oncogene to be characterized, 
discovered by Bishop and Varmus and colleagues [94]. Since this discovery, many 
other kinases have been demonstrated, primarily when mutated, to be oncogenes 
[95]. Furthermore, 244 kinases have been mapped to disease loci or cancer 
amplicons, providing further evidence for the importance of these enzymes in 
disease [93]. 
1.3.2. BCR-Abl kinase  
1.3.2.1. Overview and significance to CML 
CML is a hematopoietic cancer characterized by the expression of the 
constitutively active tyrosine kinase, BCR-Abl [96, 97]. BCR-Abl is the protein 
product of the translocation of the c-Abl gene on chromosome 9 to a specific 5.8-kD 
region on chromosome 22 termed the breakpoint cluster region (BCR). This 
abnormality is a hallmark of CML and is present in approximately 95% of CML 
patients [98]. Expression of BCR-Abl enhances molecular signaling that controls cell 
division and proliferation, such as Ras [99] and PI3K/Akt [100, 101]. Compelling 
evidence from mouse models has demonstrated the importance of BCR-Abl in CML. 
Transduction of mouse bone marrow cells with BCR-Abl is sufficient to induce 
leukemogenesis, and this technique is employed to model CML [102]. Using an 
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inducible mouse system, Huettner et al. demonstrated that expression of BCR-Abl 
developed lethal leukemia, whereas repression of BCR-Abl resulted in complete 
remission [103]. Thus, BCR-Abl is required for both the induction and maintenance 
of leukemia. 
1.3.2.2. BCR-Abl kinase signaling 
BCR-Abl kinase has enhanced activity in comparison to c-Abl [104]. Whereas 
c-Abl is primarily located in the nucleus, BCR-Abl is distributed throughout the 
cytoplasm, suggesting that it signals to different substrates [105]. Expression of 
BCR-Abl has a transformative capacity in fibroblasts and hematopoietic cells in vitro 
[106] and can induce CML in mice [107]. In addition, BCR-Abl expression activates 
multiple molecular signaling cascades to enhance cell survival and proliferation, 
including PI3K/Akt, Ras/MAPK, and JAK/STAT. 
A major substrate for BCR-Abl is the adaptor protein CRKL. The 
phosphorylation of CRKL correlates with BCR-Abl activity in CML patients and is 
used to measure the status of leukemia development [108]. CRKL forms complexes 
with BCR-Abl and important cell signaling molecules, including c-Cbl and STAT5 
[109, 110]. Disruption of BCR-Abl-CRKL complex formation strongly reduces the 
proliferation of primary CML cells and BCR-Abl-positive cell lines [111]. Furthermore, 
over-expression of CRKL in BCR-Abl transgenic mice leads to more rapid leukemia 
development [112]. 
An additional consistent regulator of BCR-Abl-dependent signaling is the 
transcription factor STAT5. RNAi-mediated silencing of STAT5 inhibited cell 
proliferation and induced apoptosis in leukocytes from CML patients [113]. 
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Expression of dominant-negative STAT5 reduced the induction and maintenance of 
CML in mice [114]. STAT proteins are a substrate of BCR-Abl kinase; however, 
studies disagree as to the importance of Janus kinases (JAKs) in the promotion of 
STAT activity and BCR-Abl-dependent leukogenesis [115, 116].  
1.3.2.3. Imatinib and mechanisms of imatinib resistance 
Developed initially as a platelet-derived growth factor receptor (PDGFR) 
inhibitor, imatinib (STI-571) is a selective and potent inhibitor of BCR-Abl and Abl 
kinase as well as the c-Kit receptor kinase [98]. The therapeutic relevance of 
imatinib was uncovered when it was observed that imatinib dramatically inhibited the 
proliferation and tumor formation of BCR-Abl-positive cells [117]. Subsequent in vitro 
and in vivo testing of this compound [117, 118] resulted in clinical trials to determine 
imatinib efficacy against CML [119] and the eventual approval of imatinib for the 
treatment of CML in 2001. Currently, imatinib is the front-line treatment for BCR-Abl-
positive CML and ALL. 
Imatinib competes for ATP binding to Abl kinase [120]. Specific mutations in 
the contact residues between imatinib and Abl and residues in the P loop and the 
kinase activation loop confer resistance to imatinib by preventing drug-induced 
inhibition [121]. Of note, the T315I mutant form of BCR-Abl is commonly found in 
imatinib-resistant patients and can confer resistance by both the prevention of 
inhibitor binding and by increasing kinase activity [122]. Other mechanisms of 
imatinib resistance include the increased expression of BCR-Abl [123] and drug 
export proteins (i.e. p-glycoprotein) [124].  
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An alternative BCR-Abl-independent mechanism of resistance is the up-
regulation of compensatory kinase signaling pathways. Burchert et al. demonstrated 
that activation of the PI3K/Akt/mTor pathway could mediate resistance in cell lines 
and primary CML cells. In addition, treatment with the mTor inhibitor rapamycin 
reversed the resistant phenotype [125]. BCR-Abl promotes cell survival through the 
activation of JAK and subsequent phosphorylation and activation of the STATs 
[126]. Therefore, it is not surprising that up-regulation of JAK2 expression can confer 
resistance to imatinib treatment [127]. 
Of specific importance to this dissertation is the mediation of imatinib 
resistance by the up-regulation of the Src family kinase (SFK) Lyn. Previous studies 
demonstrated that up-regulation and hyper-activation of Lyn kinase (Lyn) confers 
imatinib resistance in imatinib-resistant CML cell lines [128-130] and primary cells 
from patients that were non-responsive to imatinib [131]. The mechanism by which 
Lyn confers drug resistance has not been fully elucidated; however, this may involve 
the activation of GRB2-associated binder 2 (Gab2) and de-stabilization of c-Cbl 
[132]. The Lyn-dependent increase in the expression of the Bcl-2 family of proteins 
has also been attributed to a drug-resistant phenotype [128]. 
1.3.2.4. Second generation BCR-Abl kinase inhibitors 
 A minority of chronic phase CML patients is refractory to imatinib treatment or 
display secondary resistance to imatinib after therapy. However, as much as 75% of 
patients with advanced disease (accelerated phase, blast crisis) are refractory to 
treatment or relapse after initial imatinib therapy [133]. Therefore, second-line BCR-
Abl inhibitors (i.e. nilotinib, dasatinib) have been developed and are currently 
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approved for treatment of imatinib non-responsive CML patients [134]. These 
inhibitors have affinity to the BCR-Abl kinase in addition to SFKs. The hematopoietic 
SFKs Hck and Lyn are important mediators of cell survival and are often up-
regulated after imatinib treatment [135]. Moreover, SFK molecular signaling overlaps 
with that of BCR-Abl (i.e. STAT, CRKL). Thus, the efficacy of second line inhibitors is 
believed to be due to inhibition of BCR-Abl compensatory signaling.  
1.3.3. Lyn kinase in CML/AML 
1.3.3.1. Overview of Lyn kinase function 
 Lyn is a SFK member and a non-receptor tyrosine kinase. Two splice 
isoforms of this kinase exist, which differ by the excision of 21 amino acids in the N-
terminal SH4 domain (Lyn A – p56, Lyn B – p53; Yi et al., 1991). Currently, no 
functional significance has been attributed to Lyn splice variation; however, the N-
terminal region is important for kinase localization [136] and this splice site is in 
proximity to sites of lipid post-translational modification, implying splice variant-
specific localization [137]. In addition, regions within the Lyn kinase domain and N-
terminal SH4 domain are necessary for localization to Golgi membranes [138], and 
inhibition of kinase activity increases Lyn nuclear localization [139]. 
 Similar to Src kinase, Lyn activity is regulated in a phosphorylation-dependent 
manner. Lyn activity is inhibited by phosphorylation of a conserved tyrosine in the 
extreme C-terminal tail (Y508 – Lyn; Y527 – Src). Phosphorylation of this residue by 
C-terminal Src kinase (CSK) induces an inactive conformation, during which the SH2 
domain interacts with the phosphorylated tyrosine residue [140, 141]. Upon 
dephosphorylation of Y508, Lyn is trans-autophosphorylated on residue Y397 (Y416 
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– Src) within the kinase domain, inducing an activating conformational change. 
Kinase activity is attributed to phosphorylation of this tyrosine residue. However, in 
contrast to similar deletions in Src, loss of the SH2 and SH3 domains decreased Lyn 
activity, implying individual differences in the autoregulation of Lyn in comparison to 
Src [142]. 
Lyn is exclusively expressed in hematopoietic cells, particularly in cells of the 
myeloid lineage and B-cell lymphocytes [143, 144]. Lyn functions as a catalytic 
transducer of the B-cell receptor complex (BCR) and erythropoietin receptor (EpoR) 
to promote B-cell development [145] and erythrocyte differentiation [146, 147], 
respectively. In addition, stimulation of c-Kit, a cell surface receptor similar to 
PDGFR, leads to activation of Lyn, a result necessary for granulocyte colony 
stimulating factor (G-CSF)-induced cell proliferation in hematopoietic cells [148, 
149]. Thus, Lyn plays an active role in the promotion of hematopoietic cell survival. 
1.3.3.2. Lyn and drug resistance 
In myeloid cells, Lyn can both positively and negatively affect cell signaling. 
Studies using Lyn-/- mice suggest that Lyn is an inhibitor of normal myeloid cell 
development; these mice have enhanced myeloproliferation and a large number of 
cells with a blast-like phenotype [150]. However, the contribution of secondary 
inflammatory responses to the hyper-proliferation of these cells cannot be 
discounted.  
 In contrast, numerous studies have suggested that myeloid leukemias 
depend on Lyn activity. AML cell lines and primary progenitor cells display a high 
level of active Lyn [151]. Lyn associates with FLT3, a kinase that is commonly 
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mutated in AML, to mediate constitutive activation of STAT5 [152]. Treatment with 
PP2, a SFK inhibitor, prevented tumor formation and tumor growth in mice 
transplanted with AML cells expressing constitutively active FLT3 [152]. Moreover, 
Lyn is involved in many aspects of CML cell survival [131, 153].  
 Lyn over-expression and hyper-activation has been implicated in drug 
resistance in CML. Over-expression of Lyn in hematopoietic cells contributes to cell 
proliferation and drug resistance through increased STAT5 phosphorylation, Bcl-2 
expression, and other pro-survival responses [128, 129, 154]. Inhibition or 
knockdown of Lyn reduced pro-survival signaling and increased imatinib sensitivity 
in CML cells [130, 154]. Of note, therapeutic targeting of Lyn using dual SFK and 
BCR-Abl inhibitors, such as dasatinib, leads to remission in patients that are non-
responsive to imatinib [155]. Currently, dasatinib and other dual BCR-Abl/SFK 
inhibitors are FDA-approved for the treatment of imatinib-resistant CML.  
1.4. MicroRNAs and leukemia 
1.4.1. MicroRNA biogenesis 
MicroRNAs (miRNAs) are small (19-24 nt) non-coding RNA molecules that 
are key regulators of protein expression through their targeted binding to specific 
mRNAs. Since the first description of this RNA class in C. elegans [156], 
identification of numerous miRNAs has been made in both plant and animal phyla. 
There are estimated to be as many as 1000 miRNAs encoded by the human 
genome and approximately half of these have been cloned and confirmed.   
The majority of miRNAs are transcribed by RNA polymerase II as a pri-
miRNA precursor molecule (~1000-3000 bp) (Fig. 1.2). These transcripts are 
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primarily located within introns of either protein-coding or non-protein-coding 
transcripts; however, some are found within the exons of non-protein-coding 
transcripts, the 3’ UTR of mRNA, or isolated regions of the genome. In the nucleus, 
the RNAase III-like enzyme Drosha processes the pri-miRNA into one or more pre-
miRNAs (~70 bp). These pre-miRNA molecules take on a stem-loop-stem structure 
and are exported out of the nucleus by a mechanism involving exportin-5. The pre-
miRNAs are subsequently processed by Dicer RNAse III. The resulting mature 
miRNA product (~22 nt) forms a RNA duplex with target mRNAs in the RNA-induced 
silencing complex (RISC), triggering the degradation of the mRNA transcript, which 
requires complete complementarity between the miRNA and mRNA sequence, or 
the direct inhibition of protein translation [157]. It has been suggested that a single 
miRNA targets multiple mRNA transcripts and that a given mRNA has binding sites 




Figure 1.2. MicroRNA biogenesis. MicroRNAs are initially transcribed as pri-
miRNA transcripts and are subsequently processed into pre-miRNA and mature 
miRNA by Drosha and Dicer, respectively. Mature miRNA associate with the RISC 
complex and target and bind mRNA to induce translational repression or mRNA 
degradation. 
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1.4.2. MicroRNA regulation 
MiRNAs may be transcribed singly or in clusters from both intragenic (within 
the exon or intron of a transcribed RNA) and intergenic (between transcribed RNAs) 
regions of the genome. Transcriptional regulation can be imposed by epigenetic 
(methylation, acetylation, etc.) factors. For example, Agirre et al. recently 
demonstrated that hyper-methylation of the promoter region of miR124a increased 
the expression of CDK6 and contributed to enhanced cell proliferation in ALL [158].   
Transcription factors, such as CEBPα, are also important regulators of 
miRNA expression. CEBPα is a basic region leucine zipper transcription factor that 
is essential for myeloid cell differentiation and growth control and is commonly 
inactivated in AML by mutation or post-transcriptional modification [159-161]. 
CEBPα directly regulates the expression of several miRNAs, such as miR661 [162] 
and miR223 [163]. Furthermore, distinct miRNA signatures in AML have been 
attributed to the status of CEBPα activity; in particular, the up-regulation of miR181 
family is associated with CEBPα mutation [164]. These studies of transcription factor 
and miRNA expression have become increasingly important for the diagnosis of 
leukemias. 
On the post-transcriptional level, miRNAs are regulated by proteins that affect 
miRNA processing. Seminal work by the laboratories of Richard Gregory and Scott 
Hammond has elucidated the role of the RNA-binding protein Lin28 in the regulation 
of the let-7 miRNA family. Lin28 specifically interacts with the precursor let-7 
molecule to inhibit further processing by Dicer into the mature miRNA species [165, 
166]. This regulation is observed in a developmentally timed manner, and increased 
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Lin28 expression and loss of let-7 is a marker of cellular differentiation. Furthermore, 
Lin28 is a Src kinase-regulated protein [167, 168] and aberrant expression of Lin28 
has been attributed to cancer progression and Hmga2 and Ras oncogene 
expression. 
1.4.3. MicroRNAs and leukemia 
The consequences of dysregulated miRNA expression can be severe, 
resulting in developmental defects or cancer. MiRNAs may act as oncogenes to 
promote cancer progression. For instance, the miR17-92 locus encodes a cluster of 
7 microRNAs that can enhance c-Myc activity and accelerate tumor development 
[158]. Elevated expression of this cluster is associated with an aggressive cancer 
phenotype in heptacellular carcinoma [169] and lung cancer [170]. 
In addition, the loss of tumor suppressor miRNAs can enhance cell 
proliferation and cancer progression. For example, miR29a suppresses the 
expression of pro-survival genes including Myeloid Cell Leukemia-1 (Mcl-1) and 
inhibition of this miRNA using antisense antagomirs sensitizes cells to drug-induced 
cell death [171]. In addition, expression of miR29b in AML cell lines and primary 
AML cells reduces cell growth and promotes apoptosis [172]. The regulation of Mcl-1 
expression by miRNAs is an important determinant of drug sensitivity and cell 
survival. Other tumor suppressor miRNAs that target Mcl-1 include miR320 and 
miR133b [173, 174].  
Another putative tumor suppressor miRNA that has been implicated in AML is 
miR181. This miRNA family (miR181a-d) is preferentially expressed in 
hematopoietic cells and its expression can modulate cell differentiation [175]. 
 27 
Studies of AML patients have determined that the loss of miR181 is an indicator of 
poor disease prognosis and is associated with a reduced survival rate compared to 
patients with high miR181 expression [164, 176, 177]. This microRNA family is 
suggested to target Bcl-2 [178, 179], and over-expression of miR181a sensitizes 
glioma cells to ionizing radiation [178].  
1.5. Bcl-2 family proteins 
1.5.1. Overview of the Bcl-2 family 
 The B cell CLL/lymphoma-2 (Bcl-2) family of proteins is composed of both 
pro-survival and pro-death members that dictate the integrity of the outer 
mitochondrial membrane (OMM) (Fig. 1.3). The anti-apoptotic Bcl-2 proteins contain 
four Bcl-2 homology (BH1-4) domains and the major members are Bcl-2, Mcl-1, A1, 
Bcl-x, and Bcl-w. These proteins directly bind to Bcl-2 antagonist killer 1 (Bak) and 
Bcl-2 associated x protein (Bax). Bax/Bak comprise one branch of pro-apoptotic Bcl-
2 proteins and, upon homo-oligomerization, form pores within the OMM to promote 
permeabilization. After permeabilization, soluble proteins, such as cytochrome c, 
diffuse into the cytosol and activate apoptotic protease activating factor-1 (APAF-1) 
and subsequent caspase activation. Thus, blockade of Bax/Bak oligomerization 
prevents cellular apoptosis.  
 The second branch of pro-apoptotic Bcl-2 proteins are termed “BH3-only” 
proteins and consist of Bcl-2 antagonist of cell death (Bad), Noxa, Bcl-2-interacting 
domain death agonist (Bid), and Bcl-2-interacting mediator of cell death (Bim). As 
the name suggests, these proteins do not contain any of the domains found in other 
family members, with the exception of the BH3 domain. BH3-only proteins bind to 
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and inhibit anti-apoptotic Bcl-2 family members, thereby promoting apoptosis. In 
addition, Bid and Bim can directly affect Bax and Bak oligomerization to induce cell 
death [180].  
 Dysregulation of Bcl-2 protein expression can influence cell survival and is 
often a barrier to cancer therapy. Bcl-2-/- mice are embryotically viable yet undergo 
massive apoptosis in the thymus and spleen subsequent to birth [181]. Upon over-
expression, Bcl-2 suppresses apoptosis induced by a variety of agents both in vitro 
and in vivo [182, 183]. Furthermore, over-expression of pro-survival Bcl-2 proteins in 
transgenic mice results in malignancies [184, 185]. 
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Figure 1.3. Regulation of mitochondria-mediated apoptosis by the Bcl-2 family 
of proteins. Schematic depiction of mitochondria-mediated apoptosis and the 
components affected by pro- and anti-apoptotic Bcl-2 proteins (APAF, apoptotic 
protease activating factor; casp, caspase). 
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1.5.2. Unique aspects of Mcl-1 
Mcl-1 is a pro-survival Bcl-2 protein that is necessary for embryonic 
development as well as the survival of hematopoietic stem cells [186, 187]. In 
contrast to other pro-survival Bcl-2 family members, Mcl-1 does not contain a BH4 
domain in its N-terminus [188]. Rather, Mcl-1 contains two PEST sequences that 
have been shown to be important for mitochondrial localization [189]. In addition, this 
region contains JNK phosphorylation sites (S121, T163) that, upon oxidative stress-
induced phosphorylation, inhibit the anti-apoptotic function of Mcl-1 [190]. 
Phosphorylation of T163 is dynamic in that ERK-dependent phosphorylation in 
response to differentiation factor stimulation slows Mcl-1 protein turnover [191]. 
Mcl-1 is also regulated at the post-transcriptional level by microRNAs (see 
Section 1.4.3. MicroRNAs and leukemia) and alternative splicing. Splicing of exon 2 
produces Mcl-1s, which lacks the BH1, BH2, and BH4 domains. This variant is 
unable to sequester Bax and Bak, and binds to and inhibits full-length Mcl-1. Thus, 
splicing of Mcl-1 generates a pro-apoptotic protein [192]. This natural variation may 
be exploited by the use of splice-switching oligonucleotides, similar to that 
demonstrated with Bcl-x [193].  
 Mcl-1 is a high-turnover protein with a constitutive half-life of approximately 40 
minutes [194]. Mcl-1 is ubiquitinated and directed for degradation by the 
MULE/LASU1 E3 ligase [195]. Interestingly, this ligase contains a BH3 domain that 
is similar to the Bak BH3 domain, which allows for specific targeting of Mcl-1 [196]. 
As stated above, phosphorylation can affect the E3 ligase-dependent degradation of 
Mcl-1. 
 31 
1.5.3. Bcl-2 family proteins and drug resistance 
Pro-survival Bcl-2 family members are important regulators of mitochondrial 
membrane integrity and cytochrome c release and are often modulated by 
oncogenic proteins, such as BCR-Abl and FLT3-ITD [197, 198]. These proteins have 
been implicated in the promotion of drug resistance to a variety of chemotherapeutic 
drugs, including alkylating agents [199], topoisomerase inhibitors [200], 
antimetabolite drugs [201, 202], anticancer monoclonal antibody therapy [203], and 
signal transduction inhibitors [204], as well as ionizing radiation [205]. Of note, up-
regulation of Bcl-2 and Mcl-1 expression has been observed in cell models of 
imatinib-resistant CML [128, 206], and compounds that effectively inhibit imatinb-
resistant CML cell survival down-regulate Mcl-1 expression [207-209]. Furthermore, 
co-treatment of cells with siRNA against Bcl-2 members sensitizes cells to drug 
treatment [210-212].  
These observations provide rationale for the development of Bcl-2 inhibitors 
for the treatment of cancer, such as ABT-737, which has received significant 
attention due to its dramatic effects on cancer cell apoptosis. This small molecule is 
a BH-3 mimetic and targets the hydrophobic groove in pro-survival Bcl-2 proteins 
produced by BH domains 1-4 [213]. ABT-737 treatment induces cell death and 
sensitizes cells to drug treatment [213, 214]. However, due to the lack of BH4 
domain, Mcl-1 is not targeted by ABT-737; expression of Mcl-1 confers resistance to 
drug treatment [215], and down-regulation of Mcl-1 increases drug-induced cytotoxic 
effects [216]. Thus, novel Mcl-1 targeted therapies would be beneficial as an 
adjuvant to ABT-737 treatment. 
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1.6. Dissertation Summary 
 As stated above, drug resistance to anti-cancer chemotherapy is a significant 
barrier to the treatment of leukemia patients. Prolonged exposure to drug may 
induce alterations in drug transport proteins or adaptations in molecular signaling 
through alteration of kinase activity or miRNA expression. The overall goal of my 
dissertation was to identify the molecular mechanisms of drug resistance in order to 
provide substrates for the second-line chemotherapy as well as biomarkers for the 
identification of drug-resistant cancer. 
 The remainder of this dissertation is divided into 5 chapters. In chapter III, 
“Identification of a Novel Point Mutation in ENT1 that Confers Resistance to Ara-C in 
Human T-cell Leukemia CCRF-CEM Cells”, I describe that loss of ENT1 function 
due to a point mutation at G24 may explain Ara-C resistance in a cell model of ALL. 
Chapter IV, “Lyn Kinase-dependent Regulation of miR181 and Mcl-1 Expression: 
Implications for Drug Resistance in Myelogenous Leukemia”, focuses on a cell 
model of imatinib-resistant CML. In this chapter, I elucidate a novel signaling axis by 
which Lyn hyper-activation increases Mcl-1 expression through the repression of 
miR181 miRNAs. In the next chapter, “Elucidating the Mechanism(s) of miR181 
Transcriptional Regulation”, I extend these findings in an attempt to determine the 
mechanism by which Lyn regulates miR181 expression. Finally, in Chapter VI, 
“Conclusions and Future Directions”, I discuss the broad impact of these findings 























2.1. Chapter 3 materials and methods 
2.1.1. Cell culture and reagents 
The nucleoside transport-deficient swine epithelial cell line PK15-NTD (PK15) 
was generously provided by Dr. Chung-Ming Tse (School of Medicine, Johns 
Hopkins University) and was maintained as described previously [43]. The CCRF-
CEM cell line was obtained from the ATCC (Rockville, MD.) and the CCRF-CEM 
Ara-C/8C cell line, an Ara-C resistant cell line derived from the CCRF-CEM cell line, 
was kindly provided by Dr. Buddy Ullman (Dept. of Biochemistry and Molecular 
Biology, Oregon Health Sciences University). CCRF-CEM and Ara-C/8C cells were 
maintained as described previously [217]. NBMPR (6-[(4-nitrobenzyl) thio]-9-(β-d-
ribofuranosyl) purine) was purchased from Sigma-Aldrich (St. Louis, MO). [3H]-
NBMPR (specific activity: 22.0 Ci/mmol), [5, 6-3H]-Uridine (specific activity: 35-
50 Ci/mmol), and [5-3H]-Ara-C (cytosine-β-d-arabinofuranoside, specific activity: 15-
30 Ci/mmol) were obtained from Moravek Biochemicals (Brea, CA). 
2.1.2. Total RNA extraction and cDNA synthesis 
Total RNA was extracted from CCRF-CEM and Ara-C/8C cells using Trizol 
reagent (Invitrogen; Carlsbad, CA) following the manufacturer’s instruction. Two 
micrograms of total RNA were used for first-strand cDNA synthesis using oligo (dT) 
as primers (Invitrogen) and SuperScript II RNase H– Reverse Transcriptase 
(SuperScriptTM First-Strand Synthesis System for RT-PCR; Invitrogen); the 
manufacturer’s instructions were followed. 
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2.1.3. Non-quantitative RT-PCR and DNA sequencing 
One-tenth of the resulting first-strand cDNA was then used for PCR 
amplification with High Fidelity pfu DNA polymerase (Invitrogen) following the 
manufacturer’s instructions. The primers for amplifying the entire coding sequence of 
hENT1 were 5′-CCGCTCGAGATGACAACCAGTCACCTCAG-3′ (sense primer) and 
5′-AGACTCGAGTCACACAATTGCCCGGAACAGG-3′ (antisense primer). Products 
were visualized on an ethidium bromide-stained agarose gel. PCR products were 
cloned into the TOPO blunt cloning vector (Invitrogen) and expressed in DH5α E. 
Coli (Invitrogen). Plasmids were submitted for automatic sequencing (UNC-CH 
Genome Analysis Facility, http://152.19.68.152/gafsite/Main.asp). 
2.1.4. Construction of expression vectors and cell transfection 
Human ENT1 cDNA was subcloned into the pcDNA 3.1 HisC expression 
vector (Invitrogen). Construction of the G24 ENT1 mutant expression vectors was 
performed using the Quickchange Site-directed Mutagenesis kit (Stratagene; Cedar 
Creek, TX) with primers specific to ENT1; the G24R sense primer (5′-
CTTCATGCTGGGTCTGAGAACGCTGCTCCCGTGG-3′) and antisense primer (5′-
CCACGGGAGCAGCGTTCTCAGACCCAGCATGAAG-3′), G24A sense primer (5′-
CTTCATGCTGGGTCTGGCAACGCTGCTCCCGTGG-3′) and antisense primer (5′-
CCACGGGAGCAGCGTTGCCAGACCCAGCATGAAG-3′), and G24E sense primer 
(5′-CTTCATGCTGGGTCTGGAAACGCTGCTCCCGTGG-3′) and antisense primer 
(5′-CCACGGGAGCAGCGTTTCCAGACCCAGCATGAAG-3′) each confer a 
missense mutation at base pair 72. Wild-type (wt) and G24R ENT1 constructs were 
subcloned into the EGFP-C3 expression vector (Clontech; Mountain View, CA) for 
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confocal microscopy. Expression vectors were introduced into PK15 or HeLa cells 
by Lipofectamine transfection (Invitrogen) according to the manufacturer’s 
instructions. 
2.1.5. [3H]-Uridine and [3H]-Ara-C uptake assays 
The uptake of [3H]-uridine was measured in CEM cell lines or transfected 
PK15 cells exactly as described previously [218]. The same method was used to 
measure [3H]-Ara-C uptake with the substitution of cold cytidine for uridine used to 
stop the reaction. The protein concentration of each sample was quantified using 
Bradford reagent (Pierce; Rockford, IL). 
2.1.6. Confocal microscopy 
pEGFP-C3 constructs were transfected into HeLa cells using Lipofectamine 
reagent (Invitrogen) according to the manufacturer’s instructions. This cell type was 
used to obtain high transfection efficiency and ease for microscopy. Twenty-four hr 
after transfection, images were captured using a 63X oil immersion objective on a 
Zeiss LSM 510 Meta confocal microscope (Thornwood, NY). Image capture was 
resolved using a 488 nm argon laser. 
2.1.7. Isolation of membranes and [3H]-NBMPR binding assay 
Crude cell membranes from CCRF-CEM cells were prepared as described 
previously with minor modification [219]. Briefly, approximately 5x107 cells were 
washed 3 times with room temperature (r.t.) phosphate-buffered saline (PBS), 
suspended in 500 µl of ice-cold 5 mM Na2HPO4 buffer (pH 8.0), and sonicated to 
completely lyse the cells. After a 30-min incubation on ice, the cell membranes were 
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washed twice (40 000xg centrifugation for 40 min) with ice-cold 5 mM Na2HPO4 
buffer and suspended in 200 µl of the ice-cold 5 mM Na2HPO4 buffer. Binding 
assays were performed at r.t. in 10 mM Tris (pH 7.1) containing 0.01% CHAPS (3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate) (w/v) to prevent non-
specific binding of the radioligand. Incubations were initiated by adding an aliquot of 
500 µg cell membrane to r.t. 5 mM Na2HPO4 (final volume = 1 ml) containing 10 nM 
[3H]-NBMPR and were terminated after 45 min by dilution with 5 ml of ice-cold 
10 mM Tris (pH 7.1) followed by rapid filtration through Whatman GF/B filters 
(Piscataway, NJ), which were then washed once with 5 ml of ice-cold 10 mM Tris 
(pH 7.1). Radioactivity was measured by liquid scintillation using Scintisafe™ Econo-
2 scintillation fluid (Fisher Scientific; Pittsburgh, PA) on a LS6500 Multi-purpose 
Scintillation Counter (Beckman Coulter; Fullerton, CA). Non-specific binding of [3H]-
NBMPR was determined in the presence of 20 µM unlabelled NBMPR. 
2.1.8. Statistics 
 Data were analyzed using ANOVA and t-tests where appropriate using Prism 
4 software (Graphpad Software, La Jolla, CA).  
2.2. Chapter 3 addendum materials and methods 
2.2.1. Cell culture and reagents 
MYL and MYL-R human CML cells were a generous gift from Dr. Hideo 
Tanaka (Dept. of Haematology and Oncology, Hiroshima University, Hiroshima, 
Japan). Cells were cultured in RPMI 1640 medium (Invitrogen) supplemented with 
10% fetal bovine serum (Atlanta Biologicals; Norcross, GA) and 1% 
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antibiotic/antimycotic (Invitrogen). The imatinib-resistant cells (MYL-R, K562R) were 
not continuously cultured in the presence of imatinib; however, imatinib resistance 
and Lyn kinase over-expression were routinely checked and were found to be stably 
maintained. Cell cultures were maintained and incubated with drug at 37°C in a 5% 
CO2 humidified atmosphere. Imatinib was purchased from LC Laboratories (Woburn, 
MA). [3H]-NBMPR (specific activity: 22.0 Ci/mmol), [5, 6-3H]-Uridine (specific activity: 
35–50 Ci/mmol), and [5-3H]-Ara-C (specific activity: 15–30 Ci/mmol) were obtained 
from Moravek Biochemicals. All other reagents were purchased from Sigma-Aldrich 
unless otherwise indicated. 
2.2.2. Cell viability assay 
MYL and MYL-R cells were plated at 1.2x104 cells/well in 96-well plates.  
Vehicle or drug was added to wells in triplicate at the indicated concentrations and 
cells were incubated for 48 hr. After incubation, the MTS assay was performed 
according to the manufacturer’s protocol (CellTiter 96®AQueous One Solution 
Reagent, Promega; Madison, WI). Absorbance was read at 490 nm on a 
SpectraMAX plate reader (Molecular Devices; Sunnyvale, CA).   
2.2.3. Caspase 3 activity assay 
To determine caspase 3 activity, cells (6x104/well) were incubated with drug 
or vehicle at the indicated concentration in a 96-well plate. Plates were then 
centrifuged for 5 min to pellet the cells. Cells were lysed on ice with buffer containing 
250 mM HEPES (pH 7.4), 25 mM CHAPS, and 25 mM dithiothreitol. The non-ionic 
detergent disrupts the plasma membrane and releases the cytosolic proteins without 
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denaturing the caspase protein. The activity of caspase 3 in these samples was 
determined using the Caspase 3 Fluorimetric Assay Kit (CASP3F-1KT, Sigma-
Aldrich) according to the manufacturer’s instructions.  Fluorescence was measured 
using a FLUOstar Galaxy plate reader (BMG Labtech; Durham, NC) with a 360 nm 
excitation filter and a 460 nm emission filter.  
2.2.4. [3H]-Uridine and [3H]-Ara-C uptake assays 
 Transport assays were performed as described in Section 2.1.5. [3H]-Uridine 
and [3H]-Ara-C uptake assays. 3x105 cells were used for each sample. 
2.2.5. Isolation of membranes and [3H]-NBMPR binding assay 
 [3H]-NBMPR binding assays were performed as described in Section 2.1.7. 
Isolation of membranes and [3H]-NBMPR binding assay. 6x105 cells were used for 
each sample. 
2.2.6. Quantitative RT-PCR 
ENT mRNA was quantified by qRT-PCR performed on a 7500 Fast Real-
Time PCR System (Applied Biosystems; Foster City, CA) according to the 
manufacturer’s instructions. The PCR reaction mixture contained 900 nM each of the 
sense primer (5’-CTGGCTTTCTCTGTCTGCTTCA-3’) and antisense primer (5’-
CTCAACAGTCACGGCTGGAA-3’) for ENT1 or the sense primer (5’-
ATGAGAACGGGATTCCCAGTAG-3’) and the antisense primer (5’-
TCCTTCTCCAGGTCAAGATCCA-3’) for ENT2 or the sense primer (5’-
TTGTTACAGGAAGTCCCTTGCC-3’) and antisense primer (5’-
ATGCTATCACCTCCCCTGTGTG-3’) for βactin. One hundred micrograms of cDNA, 
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as well as the SYBR Green PCR master mix (Applied Biosystems), were also added 
to the reaction mixture. After an initial 10-min incubation at 95.0°C, cDNA was 
amplified by 40 cycles of 95.0°C for 15 seconds and 60°C for 1 minute. Transcript 
levels and expression fold changes between treatments were determined as 
previously described [220].  
2.2.7. Statistics 
 Data were analyzed using ANOVA and t-tests where appropriate using Prism 
4 software (Graphpad Software).  
2.3. Chapter 4 materials and methods 
2.3.1. Cell culture and reagents 
MYL and MYL-R human CML cells were obtained and cultured as described 
in Section 2.2.1. Cell culture and reagents. K562-R cells were obtained from Dr. 
Steven Grant (Massey Cancer Center, Virginia Commonwealth University; K562-
R(1)). A separate isolate of imatinib-resistant K562 cells were kindly provided by Dr. 
Nicholas Donato (Dept. of Internal Medicine, University of Michigan; K562-R(2)).  
HL-60 cells were obtained from the UNC Tissue Culture Facility. Cells were cultured 
in RPMI 1640 medium (Invitrogen) supplemented with 10% fetal bovine serum 
(Atlanta Biologicals) and 1% antibiotic/antimycotic (Invitrogen). The imatinib-resistant 
cells (MYL-R, K562R) were not continuously cultured in the presence of imatinib; 
however, imatinib resistance and Lyn kinase over-expression were routinely 
checked and were found to be stably maintained. HEK293T cells were a generous 
gift from Dr. Channing Der (Dept. of Pharmacology, UNC) and were maintained in 
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DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum and 1% 
antibiotic/antimycotic. Cell cultures were maintained and incubated with drug at 37°C 
in a 5% CO2 humidified atmosphere. Imatinib and dasatinib were purchased from LC 
Laboratories (Woburn, MA). SMARTpool siRNA was purchased from Thermo 
Scientific (Lafayette, CO). 1,25-dihydroxyvitamin D3 (1,25-D3) was purchased from 
Enzo Life Sciences International (Plymouth Meeting, PA). 
2.3.2. Nucleofection  
Plasmids and siRNA were incorporated into cells using the Amaxa 
nucleofection system (Walkersville, MD; >90% transfection efficiency with >90% cell 
viability, data not shown). Briefly, 1.0-1.5x106 cells were washed with PBS and re-
suspended in nucleofection solution (Mirus Bio LLC; Madison, WI). Cells were 
nucleofected using the T-16 nucleofector program and added to 4.5 ml of nutrient-
rich media. Cells were cultured in a 5% CO2 humidified atmosphere at 37°C for 24 hr 
before experimentation. 
2.3.3. Plasmid constructs and site-directed mutagenesis 
 The mature human miR181b sequence was cloned into the SDSA 3.0 
expression plasmid using the BglII and Xho1 restriction sites. After incorporation into 
cells, this plasmid expresses miR181b concomitantly with GFP. The Mcl-1 3’ UTR 
luciferase expression construct was a generous gift from Dr. Serge Nana-Sinkam 
(Div. of Pulmonary, Allergy, Critical Care and Sleep Medicine, Ohio State 
University). This is a psicheck-2 plasmid vector that incorporates the 3’ UTR of Mcl-1 
down-stream of the luciferase gene [174]. Site-directed mutagenesis of the miR181b 
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binding site was performed using sense (5’-
CCATTTAAAAATAGGTATGAATAAGATGACTAAGATACTAATGGGGAAGAACTG
CCCTG-3’) and antisense (5’-
CAGGGCAGTTCTTCCCCATTAGTATCTTAGTCATCTTATTCATACCTATTTTTAAA
TGG-3’) primers. The reaction mix included 1-ng template DNA, dNTPs, and forward 
and reverse primers. Touchdown PCR was performed on a thermocycler 
(Eppendorf; Hauppauge, NY); after an initial incubation at 95°C for 2 min, the 
following steps were cycled 18 times: 95°C for 50 sec, 70°C->55°C (each cycle was 
performed with a temperature 1 degree lower) for 50 sec, and 72°C for 14 min. The 
PCR product was treated with Dpn1, and DH5α E. Coli (Invitrogen) were 
transformed according to the manufacturer’s instructions. Mutation was confirmed by 
sequencing (UNC Genome Analysis Facility). 
2.3.4. Caspase 3 activity assay 
Caspase 3 activity was determined as described in Section 2.2.3. Caspase 3 
activity assay.  
2.3.5. Quantitative RT-PCR-based miRNA expression profiling 
Total RNA was extracted from 40.0x106 MYL and MYL-R cells using Trizol 
reagent (Invitrogen) according to the manufacturer’s instructions. MiRNA enrichment 
was then performed using the Small RNA Isolation Kit (SABiosciences; Frederick, 
MD), and the miRNA purity was assessed using an Agilent Bioanalyzer Chip (UNC 
Genomics and Bioinformatics Core). Finally, 100 ng of miRNA was 3’ 
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polyadenylated and converted to cDNA using the First Stand Synthesis Kit 
(SABiosciences) according to the manufacturer’s instructions.  
 Approximately 100 ng of cDNA was added to the Human Cancer RT2 miRNA 
qPCR Array (#MAH102C; SABiosciences; ~1.0 ng/well), and qRT-PCR was 
performed on an Applied Biosystems 7500 Fast Real-Time Thermocycler according 
to the manufacturer’s instructions. Melting curve analysis of the resulting transcript 
was determined. Analysis of the qRT-PCR data was performed using the RT2 
miRNA PCR Array Data Analysis program 
(http://www.sabiosciences.com/pcr/arrayanalysis.php).  
2.3.6. Quantitative RT-PCR analysis of miR181 expression 
 MiRNA 181 expression was measured using the Taqman MicroRNA Assay 
(Applied Biosystems; miR181b ID#: 001098; miR181d ID#: 001099) according to the 
manufacturer’s instructions with slight modification. Briefly, total RNA was extracted 
from cells using Trizol reagent (Invitrogen) according to the manufacturer’s 
instructions. One microgram of RNA was added to the following reaction mix: RT 
buffer, 1 mM dNTPs, U6 small nuclear RNA (snRNA) RT primers (Applied 
Biosystems; ID#: 001173), and RT primers against miR181. Twenty-five units of the 
Multiscribe RT enzyme (Applied Biosystems) were added, and the reverse 
transcription reaction was performed on a thermocycler (Eppendorf). Twenty-five 
nanograms of the resulting cDNA were added to a qPCR mix containing the Taqman 
Fast Universal PCR Master Mix (Applied Biosystems) and the PCR primer/probe 
reaction mix against either miR181 or U6 snRNA. Quantitative PCR was performed 
on an Applied Biosystems 7500 Fast Real-Time System, and data were analyzed 
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using the 7500 Fast Real-Time software (Applied Biosystems). Primer specificity 
was determined by the inclusion of a no-RT sample and melting curve analysis. 
MiRNA expression was normalized to the expression of U6 snRNA. 
2.3.7. Western blot analysis 
Cells were collected, washed twice with PBS, and lysed using RIPA buffer 
(without SDS; 150 mM NaCl, 9.1 mM Na2HPO4, 1.7 mM NaH2PO4, 1% NP-40, and 
0.5% deoxycholic acid; pH 7.4) supplemented with protease and phosphatase 
inhibitors (150 µM Na3VO4, 0.25 mM phenylmethylsulfonyl fluoride, 5 µg/ml 
leupeptin, and 10 nM microcystin). The lysate was centrifuged and the protein 
concentration was determined using Bradford reagent (Pierce). Sample buffer (2X: 
0.5 M Tris, 20% glycerol, 10% β-mercaptoethanol, 0.002 µg/ml Bromphenol blue; pH 
6.8) was added to an equal volume of total protein (30-50 µg) and the samples were 
separated by SDS-polyacrylamide gel electrophoresis. Proteins were transferred to 
a polyvinylidene difluoride membrane (Millipore; Billerica, MA). Membranes were 
blocked with 5% non-fat dry milk in Tris-buffered saline supplemented with Tween-
20 (TBST; 9.9 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20; pH 8.0) for 1 hr at r.t. 
Primary antibodies against Lyn (#sc-7274; Santa Cruz Biotechnology; Santa Cruz, 
CA), Mcl-1 (#sc-819; Santa Cruz), GFP (#G1544; Sigma), SFK pY416 (#2101; Cell 
Signaling Technology; Beverly, MA), and SFK pY527 (#2105, Cell Signaling) were 
diluted in 1% bovine serum albumin/TBST and applied to a membrane overnight at 
4°C or for 1 hr at r.t. Following the primary antib ody incubation, membranes were 
washed 3 times for 5 min in TBST. Secondary antibodies (horseradish peroxidise 
(HRP)-conjugated anti-mouse (#sc-2008) or anti-rabbit (#sc-2004) immunoglobulin; 
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Santa Cruz) diluted in 1% gelatin/TBST were then applied to the membrane for 1 hr 
at r.t. β-actin (#sc-47778; Santa Cruz) or α-tubulin (#T9026; Sigma) expression was 
measured as a loading control. Membranes were developed using enhanced 
chemiluminescence (ECL; GE Healthcare, Piscataway, NJ) with exposure to 
autoradiography film. Densitometry was performed using a FluorChem FC2 imager 
(Cell Biosciences, Santa Clara, CA).  
2.3.8. Transfection and luciferase activity assay 
HEK293T cells (3x105/well) were plated in poly-L-lysine-treated 6-well plates.  
The next day, cells were transfected using Lipofectamine reagent (Invitrogen) 
according to the manufacturer’s instructions.  
 Twenty-four hr after transfection, cells were lysed at r.t. with RIPA buffer 
(without SDS).  The lysate was centrifuged for 10 min at 10000 RPM.  Ten-microliter 
aliquots of each sample were applied to a 96-well plate, and 150 µl of the luciferase 
assay reaction mix (25 mM glycyl glycine, 15 mM MgSO4, 15 mM KPO4, 4 mM 
EGTA, pH 7.8) containing 0.1 mg/ml luciferin (Sigma) was added to each well. 
Luciferase activity was measured on a Pherastar luminometer (BMG Labtech).  
Western blot analysis of GFP was performed to ensure equivalent transfection, and 
β-actin expression was determined as a loading control. 
2.3.9. Statistics 
 Data were analyzed using ANOVA and t-tests where appropriate using Prism 
4 software (Graphpad Software).  
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2.4 Chapter 4 supplemental methods 
2.4.1. Quantitative RT-PCR analysis of miR181b expression 
Quantitative RT-PCR of individual miR181b expression was performed using 
the method of Thomson et al, 2006. Briefly, 10 µg of total RNA was DNAse 
(Promega) treated and then polyadenylated using Poly(A) polymerase (Applied 
Biosystems) according to the manufacturer’s instructions. Two micrograms of RNA 
were then reverse transcribed by the Superscript II reverse transcriptase (Invitrogen) 
using the oligo(dT) adapter primer (5’-
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN-3’) according 
to the manufacturer’s instructions. Quantitative RT-PCR was performed on a DNA 
Engine Opticon 2 thermocycler (MJ Research; Waltham, MA) using 25 ng of cDNA. 
An exact sequence-specific sense primer was used for miR181b in conjunction with 
a universal antisense primer (5-GCGAGCACAGAATTAATACGACTCAC-3). Sense 
(5’-CTCGCTTCGGCAGCACA-3’) and antisense (5’-AACGCTTCACGAATTTGCGT-
3’) primers were used to amplify the U6 snRNA transcipt. The PCR reaction cocktail 
was mixed with the SYBER green master mix (Applied Biosystems) and qPCR was 
performed using the following profile: 10 min incubation at 95.0°C followed by 40 
cycles of 95.0°C for 15 sec and 60°C for 1 min.  Primer specificity was determined 
by the inclusion of a no-RT sample and melting curve analysis. MiRNA expression 
was normalized to the expression of U6 snRNA.  
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2.4.2. Plasmid constructs and cell transfection 
 The pENTR Lyn kinase (A isoform) Gateway expression construct 
(Invitrogen) was a generous gift from Dr. David Lawrence (Div. of Medicinal 
Chemistry and Natural Products, UNC School of Pharmacy). The Lyn kinase 
expression construct was subcloned into the pLenti6.2/V5-DEST vector (Invitrogen) 
according to the manufacturer’s instructions. HEK293T cells were transfected using 
Lipofectamine reagent (Invitrogen) according to the manufacturer’s instructions. 
2.4.3. Lyn kinase peptide construction and peptide-based Lyn activity assay 
 A fluorochrome-conjugated peptide containing a Lyn consensus 
phosphorylation site was developed as described in Wang et al., 2010. Lyn activity 
was determined in MYL and MYL-R cells using a peptide-based assay as described 
in [221]. 
2.5. Chapter 5 materials and methods 
2.5.1. Cell culture and reagents 
 MYL, MYL-R, and HEK293T cells were obtained and maintained as described 
in Section 2.2.1. Cell Culture and Reagents. Cell cultures were incubated with drug 
at 37°C in a 5% CO 2 humidified atmosphere. Trichostatin A and Valproic acid were a 
generous gift from Dr. Pilar Blancafort (Dept. of Pharmacology, UNC). 5-aza-C was 
obtained from Sigma-Aldrich. Go6983, H89, and U0126 were purchased from Enzo 
Life Sciences International. SNX5422-conjugated beads were a kind gift from Dr. 
Tim Haystead (Dept. of Pharmacology and Cancer Biology, Duke University).  
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2.5.2. Phospho-kinase antibody array 
 Kinase activity was profiled using the Proteome Profiler Human Phospho-
kinase Array System (#ARY003; R and D Systems, Minneapolis, MN) according to 
the manufacturer’s instructions. Briefly, cells were lysed in buffer supplied by the kit. 
After a blocking step, membranes were incubated with total cell lysate (500 µg) 
overnight at 4°C. This was followed by 3 washes in buf fer supplied by the kit for 10 
min each. Membranes were then incubated with a secondary antibody solution for 2 
hr at r.t. After a 3 x 10 min wash, membranes were incubated with a streptavidin-
HRP solution for 30 min. A final 3 x 10 min wash was followed by incubation with 
ECL reagent (Thermo Scientific) and exposure to autoradiography film. 
Densitometry was performed using a FluorChem FC2 imager (Cell Biosciences). 
2.5.3. Western blot analysis 
 Western blot analysis of protein expression was performed as described in 
Section 2.3.7. Western blot analysis. Antibodies against pLyn (Y397; #2101), 
pCREB (S133; #9191), CREB (#9192), pSTAT5 (Y694; #9351), and STAT5 (#9363) 
were purchased from Cell Signaling Technology. Antibodies against histone H3-Ac 
(K27 (#39135) and K18 (#39755)), histone H3K4me2 (#39913), and histone H4-
tetra-Ac (#39177) were purchased from Active Motif (Carlsbad, CA). Antibodies 
against histone H3 were a generous gift from Dr. Brian Strahl (Dept. of Biochemistry, 
UNC). Antibodies against HSP90 (#13119) were purchased from Santa Cruz 
Biotechnology. 
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2.5.4. Total RNA extraction and cDNA synthesis 
Total RNA was extracted from cells and cDNA was synthesized as described 
in Section 2.1.2. Total RNA extraction and cDNA synthesis. 
2.5.5. Non-quantitative RT-PCR and DNA sequencing 
Twenty-five nanograms of the resulting first-strand cDNA were then used for 
PCR amplification with High Fidelity pfu DNA polymerase (Invitrogen). The primers 
for amplifying pri-181b-1 were 5′-CGGCCATGTTTTTGCTTAATT-3′ (sense primer) 
and 5′-TCCACCTTTGGTTTCCTGTC-3′ (antisense primer). The primers for 
amplifying pri-181b-2 were 5′-CCCCACCAACTGAAAACACT-3′ (sense primer) and 
5′-CAGTAGCTGCTGCACTCAGG-3′ (antisense primer). The primers for amplifying 
β2M were 5′-GAATTGCTATGTGTCTGGT-3′ (sense primer) and 5′-
CATCTTCAAACCTCCATGATG-3′ (antisense primer). The PCR reaction was 
performed on a thermocycler (Eppendorf) as follows: 94°C for 30 sec followed by 30 
cycles of 94°C for 20 sec, 56.2°C for 30 sec, and 72°C for 30 sec. Products were 
visualized on an ethidium bromide-stained agarose gel. Densitometry was 
performed using a FluorChem FC2 imager (Cell Biosciences). 
2.5.6. Quantitative RT-PCR analysis of miR181 expression 
 MiRNA 181 expression was measured using the Taqman MicroRNA Assay 
(Applied Biosystems; miR181b ID#: 001098; miR181d ID#: 001099; miR181c ID#: 
000482) as described in Section 2.3.6. Quantitative RT-PCR analysis of miR181 
expression.  
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2.5.7. Nucleofection  
Nucleofection was performed as described in Section 2.3.2. Nucleofection.  
2.5.8. Statistics 
 Data were analyzed using ANOVA and t-tests where appropriate using Prism 
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3.1. Abstract 
The genetic basis for the Ara-C resistance of CCRF-CEM Ara-C/8C leukemia 
cells was investigated. DNA sequencing revealed that these cells expressed an 
equilibrative nucleoside transporter 1 (ENT1) with a single missense mutation 
resulting in glycine to arginine replacement (G24R). To test the importance of this 
residue, additional G24 mutants were created and examined for [3H]-uridine and 
[3H]-Ara-C uptake. Both a G24E and G24A mutant showed reduced ENT1-
dependent activity. An EGFP-tagged G24R ENT1 displayed plasma membrane 
localization even though it was unable to bind [3H]-NBMPR, an ENT1-specific 
inhibitor. These results define G24 as critical amino acid for ENT1 nucleoside uptake 
and suggest that mutations in TM1 may provide a mechanism for Ara-C resistance 
in CCRF-CEM Ara-C/8C cells. 
3.2. Introduction 
Cytarabine (Ara-C), a pyrimidine analog, is a conventional anti-cancer 
chemotherapeutic commonly used for the treatment of acute myeloid leukemia. Ara-
C is a hydrophilic molecule that achieves intracellular penetration via nucleoside 
transporter proteins. Once inside the cell, this agent exerts cytotoxic effects on 
proliferating cancer cells by the direct inhibition of DNA polymerases and the arrest 
of DNA synthesis. Although Ara-C treatment often induces partial or complete 
remission of cancerous tissue, many patients eventually develop resistance [222]. 
Thus, understanding the mechanisms of resistance is important for the development 
of effective anti-cancer therapies. 
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CCRF-CEM Ara-C/8C (Ara-C/8C) cells, a nucleoside transport-deficient T-cell 
leukemia cell line, were isolated by single cell cloning and resistance to Ara-C; these 
cells demonstrate cross-resistance to gemcitabine and 2′,3′-dideoxycytidine [217, 
223]. Despite these observations, the molecular defect responsible for the loss of 
nucleoside transport in these cells was not elucidated. 
The equilibrative nucleoside transporters (ENTs) are a sodium-independent 
class of nucleoside transporters (SLC29) responsible for the uptake of a large 
number of nucleosides and nucleoside analogs [42]. This includes purine and 
pyrimidine nucleosides and analogs such as gemcitabine, Ara-C, and fludarabine 
[224-226]. Four distinct members of this class of proteins have been identified 
(ENT1-4) [42]. ENT1 and ENT2 are the best-characterized members of this family; 
ENT1 is selectively inhibited by nitrobenzylthioinosine (NBMPR), whereas both 
ENT1 and ENT2 are inhibited by dipyridimole and dilazep [219]. In comparison, 
ENT3 is distributed mainly within endomembranes [227] and studies suggest ENT4 
may function as a monoamine/organic anion transporter [228, 229]. 
ENTs share a common 11-transmembrane (TM) ∝-helix topology [48] and 
structure-function studies suggest that amino acid residues within TM 3-6 may be 
involved in nucleoside binding [53, 54]. For example, site-directed mutagenesis of 
human ENT1 expressed in Saccharomyces cerevisiae demonstrated that glycine 
179 in TM5 was required for uridine transport and sensitivity to NBMPR, whereas 
glycine 184 may partially determine targeting of the transporter to the plasma 
membrane [53]. Similarly, glycine 154 was reported to be important for nucleoside 
transport and sensitivity to the inhibitors NBMPR, dipyridamole and dilazep [54]. 
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However, recent studies suggest that amino acids in TM domains other than 3-6 
may also be critical for the transport of nucleoside substrates and their analogs [55]. 
Specifically, methionine 33 in TM1 and isoleucine 429 in TM11 of human ENT1, 
human ENT2, and Caenorhabditis elegans ENT1 were reported to be required for 
nucleoside transport and may contribute to the binding of dipyridamole [55]. A report 
by Paproski et al. demonstrated that tryptophan 29 within TM1 was important for 
inhibitor binding and ENT1 proteins containing mutations of W29 have altered 
nucleoside transport kinetics [56]. 
In our study we identified a single point mutation at glycine 24 in TM1 of 
ENT1 in Ara-C/8C cells. To investigate the importance of G24, we developed ENT1 
proteins with different point mutations of glycine 24 and expressed these mutants in 
PK15 cells, a nucleoside transport-deficient cell line. The mutant ENT1 proteins 
were defective in transport activity, as measured by [3H]-uridine and [3H]-Ara-C 
uptake and inhibitor binding. Thus, mutation of glycine 24 in ENT1 may explain the 
loss of nucleoside transport and resistance to nucleoside analogs in Ara-C/8C cells. 
3.3. Results 
3.3.1. Functional loss of ENT1 activity in Ara-C/8C cells is independent of 
mRNA expression 
The nucleoside transport-deficient Ara-C/8C cells were isolated as a cell line 
highly resistant to Ara-C and gemcitabine [217, 223]. Comparison of [3H]-uridine 
uptake in parental and resistant CEM cells showed that the Ara-C/8C were 
completely deficient in uridine uptake (Fig. 3.5.1A). [3H]-Uridine uptake was 
abolished with the ENT1-specific inhibitor NBMPR in the parental CCRF-CEM cells, 
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demonstrating that ENT1 activity accounts for the majority of uridine transport in the 
CEM cell lines. In comparison, the binding of [3H]-NBMPR to crude membrane 
preparations of Ara-C/8C cells was almost completely abolished (Fig. 3.5.1B), 
suggesting that functional ENT1 protein was absent from Ara-C/8C cells. 
ENT1 mRNA expression was determined using non-quantitative RT-PCR. As 
shown in Figure 3.5.1C, Ara-C/8C cells expressed similar levels of ENT1 mRNA as 
compared to the parental CCRF-CEM cells. This observation suggests that the 
defect in nucleoside uptake was independent of ENT1 expression. 
3.3.2. Identification of a point mutation in ENT1 from Ara-C/8C cells that 
disrupts transport activity 
We next determined whether ENT1 from the Ara-C/8C cell line contained 
mutations that would explain a loss of function. Full-length ENT1 was amplified by 
PCR and sequenced. Analysis of the ENT1 sequence revealed a single nucleotide 
missense mutation resulting in the substitution of arginine for glycine at amino acid 
position 24 (GGA to AGA). Complete sequence analysis of ENT1 from Ara-C/8C 
cells did not reveal any additional mutations. G24 is located in the TM1 domain of 
ENT1 and is conserved amongst species and ENT2 isoforms (Fig. 3.5.2A). 
We created several point mutations of G24; substitution of alanine and 
glutamate were performed to determine the effect of amino acid size and charge on 
ENT1 function. Wt ENT1 and G24A, G24E, and G24R ENT1 mutants were 
transfected into nucleoside transport-deficient PK15 cells and [3H]-uridine uptake 
was measured as an index of ENT1 activity. As shown in Figure 3.5.2B, G24R ENT1 
was deficient in [3H]-uridine transport compared to wt ENT1. ENT1 proteins with a 
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mutation of G24 to alanine or glutamate displayed only partial transport activity when 
compared to wt ENT1 (Fig. 3.5.2B). Similarly, the G24R ENT1 mutant displayed a 
deficiency in [3H]-Ara-C uptake; G24A ENT1 displayed partial uptake when 
compared to wt ENT1, whereas G24E ENT1 was uptake-deficient (Fig. 3.5.2C). 
These data further indicate that glycine 24 is important for ENT1 activity and 
mutation of G24 severely reduced transport activity. 
3.3.3. The G24R ENT1 mutant maintains plasma membrane localization but is 
deficient in NBMPR binding 
To determine if the G24R ENT1 mutant was localized to the plasma 
membrane as expected, wt and G24R ENT1 proteins were subcloned into the 
pEGFP-C3 vector. Transfection of HeLa cells showed that the G24R ENT1 mutant 
exhibited predominantly membranous expression, similar to that observed with wt 
ENT1 (Fig. 3.5.3A). These data demonstrated that the G24 mutation did not alter 
protein maturation or plasma membrane localization. To investigate whether the 
G24R ENT1 mutant was sensitive to inhibitor binding, [3H]-NBMPR binding assays 
were conducted with crude cell membrane preparations from PK15 cells expressing 
either wt or G24R ENT1. [3H]-NBMPR has selective affinity for ENT1 and inhibitor 
binding to cells expressing wt ENT1 was observed (Fig. 3.5.3B). In contrast, cells 
expressing the G24R ENT1 mutant did not display any detectable [3H]-NBMPR 




In this study, we provide evidence for a novel missense mutation in ENT1 that 
conferred resistance to nucleoside uptake in an Ara-C-resistant cell line of CCRF-
CEM cells. Our results demonstrate that a single point mutation (G24R) in TM1 
results in the generation of an inactive ENT1. G24 is an amino acid that is highly 
conserved between ENT isoforms and amongst species, suggestive of its 
importance to hENT1 function. Substitution of G24 with amino acids that vary in size 
and charge confirmed the importance of G24 in ENT1 recognition of substrates. 
Moreover, G24 may be an important contact for inhibitor recognition since G24R 
mutants of ENT1 did not bind [3H]-NBMPR. Partial [3H]-Ara-C transport was 
observed with the G24A mutation, which may be due to the similarity of the amino 
acids. Importantly, our data suggest that differences in ENT1 G24 mutant activity 
were not due to differential expression but due to a functional difference since the wt 
and G24R ENT1 proteins had dissimilar [3H]-uridine transport/[3H]-NBMPR binding 
ratios (2.54 ± 0.10 vs. 0.67 ± 0.02). Thus these studies are the first to identify this 
conserved amino acid as an important determinant for nucleoside recognition and 
uptake. 
The G24R point mutation in ENT1 may affect several processes related to the 
functional activity of ENT1, including substrate binding, protein folding or targeting of 
ENT1 to the plasma membrane. Topology predictions (SOSUI program; 
http://bp.nuap.nagoya-u.ac.jp/sosui/) suggest that G24R ENT1 is capable of 
targeting to plasma membrane similarly to the wt ENT1. This prediction is supported 
by our data showing similar membranous localization of EGFP-tagged wt and G24R 
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ENT1. Our studies also show that G24R ENT1 is incapable of binding the inhibitor 
NBMPR. This may result from a disruption of the substrate-binding site since 
NBMPR, a purine analog, is expected to bind at or near the substrate-binding pocket 
[53, 54]. Recent studies have shown that amino acids in close proximity (M33 and 
W29) are important to ENT1 nucleoside transport and inhibitor binding [55, 56]. 
Based on these observations, we speculate that the G24R substitution at this 
position similarly interferes with binding of nucleosides and nucleoside analogs to 
ENT1. Thus, TM1 may be a topologically-sensitive portion of ENT1, making the 
proper orientation of TM1 necessary for protein function. 
ENT-mediated transport of nucleoside analogs is often the rate-limiting step 
for drug-induced cell cytotoxicity [225]. Thus, it is not surprising that studies have 
found a positive correlation between the expression of ENT1 and cancer cell 
sensitivity to the nucleoside analogs Ara-C [81] and gemcitabine [230]. The 
reduction in ENT1 expression is a common mechanism for resistance to 
antimetabolite treatment of cancer [226, 231]. In addition, a recent study using an 
Ara-C-resistant CCRF-CEM cell line reported that genetic mutations of ENT1 that 
alter mRNA splicing and protein translation provide mechanisms for resistance to 
drug treatment [89]. 
In conclusion, these studies provide new information on the specific role of 
G24 within the TM1 domain of ENT1 in nucleoside recognition and uptake. 
Expression of a G24R ENT1 mutant provides the first molecular explanation for the 
loss of ENT1-dependent nucleoside uptake in the Ara-C/8C cells and indicates that 
mutation of this amino acid could result in resistance to Ara-C treatment. 
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3.5. Figures 
Figure 3.5.1. Comparison of [3H]-uridine uptake, [3H]-NBMPR binding, and 
ENT1 mRNA expression between CCRF-CEM cells and Ara-C/8C cells. A) 3x105 
CCRF-CEM and Ara-C/8C cells (CEM-AraC-8C) cells were incubated with [3H]-
uridine in sodium-free transport buffer for 5 min in the presence or absence of 
1.0 µM NBMPR, a selective inhibitor of ENT1. Data represent the mean ± S.D. of 
four experiments performed with duplicate samples (*, p< 0.01 different from -
NBMPR; #, p< 0.01 different from parental cell line, -NBMPR). B) [3H]-NBMPR 
binding was performed using isolated membranes from 3x105 CCRF-CEM and 
CEM-AraC-8C cells as described in Section 2.1.7. Isolation of membranes and [3H]-
NBMPR binding assay. Data represent the mean ± S.D. of two experiments 
performed with triplicate samples (*, p < 0.01). C) Total RNA was extracted from 
3x105 CCRF-CEM and CEM-AraC-8C cells. ENT1 mRNA expression in CCRF-CEM 
and CEM-AraC-8C cells was determined by non-quantitative RT-PCR. A 
representative gel is shown. 
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Figure 3.5.2. Substitution of G24 in ENT1 disrupts nucleoside and Ara-C 
transport activity. A) Alignment of amino acids 13–33 of ENT1 and ENT2 from 
different species using ClustalW software (http://align.genome.jp/). Arrow denotes 
residue G24 (TM1, transmembrane domain 1). B) Wt ENT1 and G24A, G24E, and 
G24R ENT1 mutants were expressed separately in PK15 cells (6x104) and [3H]-
uridine uptake was performed for 20, 40, and 60 min. The average transport by wt 
ENT1 was approximately 4.19 pmol/min/mg protein. Data represent the mean ± S.D. 
of samples in quadruplicate (*, p<0.01 different from 0 min). (C) Wt ENT1 and G24A, 
G24E, and G24R ENT1 mutants were expressed separately in PK15 cells (6x104) 
and [3H]-Ara-C uptake was performed for 2 hr in the presence or absence of 1 µM 
NBMPR. Average transport by wt ENT1 was approximately 2.08 pmol/min/mg 
protein. Data represent the mean ± S.D. of samples in quadruplicate (*, p < 0.01 





Figure 3.5.3. The G24R ENT1 mutant lacks [3H]-NBMPR binding even though 
plasma membrane expression is maintained. A) Wt and G24R ENT1-GFP 
proteins were expressed in HeLa cells and observed using confocal microscopy. 
Representative images are shown. Arrows denote approximate plasma membrane 
location. B) Wt ENT1 and G24R ENT1 were transfected separately into PK15 cells 
(6x104). Forty-eight hr post-transfection, cells were lysed, the membranes were 
isolated, and [3H]-NBMPR binding to the isolated membrane was determined as 
described in Section 2.1.7. Isolation of membranes and [3H]-NBMPR binding assay. 
Data represent the mean ± S.D. of two experiments performed with triplicate 
samples (*, p < 0.01). 
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3.6. Addendum 
 Our initial focus on ENT1-dependent mediation of Ara-C drug resistance 
highlights the role of drug permeability factors in chemotherapy and the necessity for 
drug access to permit cytotoxic drug action. Much research is dedicated to the 
understanding of drug transporter-dependent effects on drug pharmacokinetics, 
pharmacodynamics, and drug-induced cell death. Dysfunction of active transport is a 
common mechanism underlying resistance to antimetabolite therapy, as indicated by 
numerous clinically relevant publications describing these mechanisms [91]. 
However, transporter-independent resistance mechanisms are also prominent in 
leukemia.  
 Our studies of ENT1 expression and activity in drug-resistant cell lines 
uncovered examples where ENT activity did not correlate with sensitivity to 
nucleoside analogs. Notably, we measured ENT1 and ENT2 expression and activity 
in the BCR-Abl-transformed mouse 32Dp185 cell line that was made resistant to the 
BCR-Abl inhibitor imatinib [232]. The primary findings of this study were that 1) 
imatinib treatment of the imatinib-sensitive 32Dp185 cells decreased ENT1 mRNA 
expression and transport activity and 2) the imatinib-resistant 32Dp185 STI-R cells 
were sensitive to gemcitabine treatment even though these cells express less ENT1 
and ENT2 and display low ENT activity [232]. Thus, ENT expression was not a 
limiting factor to the cytotoxic effects of nucleoside analog treatment and did not 
correlate with gemcitabine sensitivity. 
 Furthermore, we found that a human chronic myelogenous leukemia (CML) 
cell line resistant to imatinib, termed MYL-R, were cross-resistant to the nucleoside 
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analogs gemcitabine and Ara-C. Cells were resistant to drug in a dose-dependent 
manner as assessed by MTS assay and caspase 3 activity (Fig. 3.7.1A-D). 
Therefore, we measured ENT1 and ENT2 expression using qRT-PCR to determine 
whether dysregulation of these transporters caused resistance to these nucleoside 
analogs. Surprisingly, both ENT1 and ENT2 mRNA expression was similar between 
the drug-sensitive MYL cells and the drug-resistant MYL-R cells (Fig. 3.7.2A). In 
agreement with the qRT-PCR data, ENT1 expression was not significantly different 
between the two cell lines as assessed by [H3]-NBMPR binding (Fig. 3.7.2B).   
To measure transporter activity, [3H]-uridine uptake was determined in MYL 
and MYL-R cells. Pre-incubation with NBMPR, an ENT1-selective inhibitor, or 
dipyridamole, an ENT1 and ENT2 inhibitor, was performed to assess the individual 
contribution of these transporters. As shown in Figure 3.7.3A, overall transport of 
[3H]-uridine was not significantly different between MYL and MYL-R cells. After 
inhibition of ENT1 only or both ENT1 and ENT2, [3H]-uridine uptake remained similar 
between the cell lines (Fig. 3.7.3A). In addition, our data suggest that ENT1- and 
ENT2-mediated transport accounted for approximately 50% of [3H]-uridine uptake in 
both cell lines; non-ENT-mediated transport of the substrate may be due to the 
presence of CNTs or other dipyridamole insensitive transporters. To confirm the [3H]-
uridine transport data, we measured the uptake of [3H]-Ara-C. In order to exclude the 
contribution of CNTs to uptake, we performed this experiment in the absence of 
sodium, which is necessary for CNT-mediated transport. Similar to the [3H]-uridine 
uptake data, transport of [3H]-Ara-C was not significantly different between MYL and 
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MYL-R cells (Fig. 3.7.3B). Thus, unlike the CCRF-CEM model, ENT expression and 
activity did not correspond with drug resistance in MYL-R cells. 
 Collectively, these findings suggest that ENT expression may not always be 
prognostic for drug resistance. Thus, as discussed in Chapter 4, we focused on 
kinase-dependent mechanisms of drug resistance through regulation of apoptotic 
machinery.
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3.7. Addendum figures 
Figure 3.7.1. MYL-R cells are resistant to imatinib and nucleoside analogs. A-
C) MYL (open triangles) and MYL-R (closed squares) cells were plated in 96-well 
plates (1.2x104/well) and cultured in the presence of vehicle or drug at the indicated 
concentrations for 48 hr. Cell viability was determined using the MTS assay as 
described in Section 2.2.2. Cell viability assay. Data represent the mean ± S.D. of 
triplicate samples (***, p<0.001). D) Cells were plated in a 96-well plate (6x105) and 
cultured with vehicle or drug for 24 hr. Caspase 3 activity was measured as 
described in Section 2.2.3. Caspase 3 activity assay. Data represent the mean ± 
S.D. of triplicate samples (***, p<0.001). 
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Figure 3.7.2. ENT expression is similar between MYL and MYL-R cells. A) Total 
RNA was extracted from 2x106 cells and mRNA expression was determined by qRT-
PCR. Data represent the mean ± S.E.M. of triplicate samples. B) 6x105 cells were 
incubated with the indicated amount of [3H]-NBMPR and the amount of bound [3H]-
NBMPR was determined by scintillation counting. Data represent the mean ± S.D. of 
triplicate samples. 
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Figure 3.7.3. MYL and MYL-R cells have similar transport activity. A) 3.0x105 
cells were treated with DMSO, 1.25 µM NBMPR, or 2.0 µM dipyridamole for 15 min 
and then were incubated with [3H]-uridine for 10 min in the presence of inhibitor. B) 
3.0x105 cells were incubated with [3H]-Ara-C for 45 min and the uptake of radioactive 
substrate was determined by scintillation counting. Data represent the mean ± S.D. 
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4.1. Abstract 
The BCR-Abl inhibitor imatinib is a successful front-line treatment for chronic 
myelogenous leukemia (CML). However, despite the success of imatinib, multiple 
mechanisms of resistance remain a problem, including over-expression of Lyn 
kinase (Lyn) and Bcl-2 family anti-apoptotic proteins. Profiling miRNA expression in 
a model of Lyn-mediated imatinib-resistant CML (MYL-R) identified approximately 30 
miRNAs whose expression differed >2-fold in comparison to drug-sensitive MYL 
cells. In particular, the expression of the miR181 family (a-d) was significantly 
reduced (~11-25 fold) in MYL-R cells. Incubation of MYL-R cells with a Lyn inhibitor 
(dasatinib) or nucleofection with Lyn-targeted siRNA increased miR181b and 
miR181d expression. A similar Lyn-dependent regulation of miR181b and miR181d 
was observed in imatinib-resistant K562 CML cells. Sequence analysis of potential 
targets for miR181 regulation predicted Mcl-1, a Bcl-2 family member whose 
expression is increased in MYL-R cells and drug-resistant leukemias. Inhibition of 
Lyn or rescue of miR181b expression reduced Mcl-1 expression in the MYL-R cells. 
To further investigate the mechanism of Mcl-1 repression by miR181, a luciferase 
reporter construct incorporating the Mcl-1 3’ UTR was tested. Over-expression of 
miR181b reduced luciferase activity, whereas these effects were ablated by 
mutation of the seed region of the miR181 target site. Lastly, stimulation of Lyn 
expression by 1,25-dihydroxyvitamin D3 treatment in HL-60 cells, a cell model of 
acute myelogenous leukemia, decreased miR181b expression and increased Mcl-1 
expression. In summary, our results suggest that Lyn-dependent regulation of 
miR181 is a novel mechanism of regulating Mcl-1 expression and cell survival.   
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4.2. Introduction 
The discovery and application of the BCR-Abl inhibitor imatinib has been a 
major hallmark in the development of kinase inhibitors for cancer chemotherapy. 
However, despite the success of imatinib for the treatment of chronic myelogenous 
leukemia (CML) and other cancers, multiple mechanisms of imatinib resistance have 
been identified. These include BCR-Abl mutations that prevent imatinib binding (i.e. 
T315I) [233, 234], BCR-Abl over-expression [233], and increased expression and 
activity of Src family kinases (SFKs) or other pro-survival proteins [124, 235]. 
Recently, Lyn kinase (Lyn) has been implicated in imatinib resistance in both CML 
cells and patient samples. Over-expression of Lyn, the most abundant SFK in 
myeloid cells, may contribute to drug resistance through increased STAT5 
phosphorylation, Bcl-2 expression, and other pro-survival responses [128, 129, 154]. 
Inhibition of Lyn with SFK inhibitors reduced pro-survival signaling and reversed 
imatinib resistance in CML cells [130, 154]. Moreover, dual-BCR-Abl/SFK inhibitors 
(i.e. dasatinib, nilotinib) effectively treat patients that are non-responsive to imatinib 
therapy [131, 235].   
 MicroRNAs (miRNAs) are small (22-24 nt) non-coding RNA molecules that 
are key regulators of protein expression through their targeted binding to specific 
mRNAs. By forming a double-stranded RNA duplex with target mRNAs in the RNA-
induced silencing complex (RISC), miRNAs trigger the degradation of the mRNA 
transcript or directly inhibit protein translation [157]. Over 700 miRNAs have been 
described in humans, and patterns of deletion, down-regulation, or up-regulation of 
specific miRNAs have been characterized in B-cell chronic lymphocytic leukemia 
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(CLL), acute myelogenous leukemia (AML), and CML [236-238]. Recent studies 
have demonstrated the importance of the miR181 family (a-d) expression in AML 
and CLL. MiR181a is involved in hematopoietic differentiation [175], and loss of 
miR181 strongly correlates with a common AML morphological subtype [239]. 
Moreover, high miR181 (a-d) expression is prognostic for the achievement of 
complete remission and event free survival in AML patients [164, 176, 177].  
 Bcl-2 family members are important pro-survival regulators of apoptosis that 
have been implicated in the promotion of drug resistance in cell models of leukemia 
[128, 240, 241]. Myeloid Cell Leukemia-1 (Mcl-1) is a Bcl-2 family protein shown to 
correlate with leukemic relapse in AML and has been directly linked to resistance to 
chemotherapy [242]. In addition, Mcl-1 was recently implicated in AML survival in 
response to FLT-3 internal tandem duplication (FLT3-ITD), a common mechanism of 
resistance in AML that involves the activation of Lyn [152, 204]. Mcl-1 functions at 
the mitochondria by sequestering the pro-apoptotic BH3-only proteins Bim and 
Noxa, thereby preventing cytochrome c release and cell death [243]. Mechanisms to 
inhibit Mcl-1 function include ubiquitination and degradation directed by the 
MULE/LASU1 E3-ligase [195], and targeting of Mcl-1 mRNA for degradation by 
miRNA has been described [171, 173, 174].   
 In this study, we describe a novel mechanism by which Lyn may confer multi-
drug resistance in a cell model of CML by repressing the expression of miR181. As 
our data show, miR181b directly represses Mcl-1 expression and the Lyn-dependent 
loss of miR181 results in enhanced Mcl-1 levels and increased drug resistance. 
Thus, this is the first demonstration, to our knowledge, of Mcl-1 as a bona fide target 
 72 
of miR181 and suggests that the regulation of miR181 by Lyn in drug-resistant cells 
may contribute to this important anti-apoptotic mechanism. 
4.3. Results 
4.3.1. Lyn kinase over-expression in MYL-R cells confers drug resistance 
Previous studies have demonstrated that Lyn is important for MYL-R survival 
and imatinib resistance [130]. To compare Lyn expression and activity, lysates of 
MYL and MYL-R cells were Western blotted with antibodies that recognize total Lyn, 
active Lyn (P-Y397 (P-Y416 Src)), or inactive Lyn (P-Y507 (P-Y527 Src)).  As shown 
in Figure 4.5.1A, the Lyn B splice form (53 kDa) was significantly over-expressed 
and phosphorylated on the activation loop (Y397), indicating increased activity in 
MYL-R cells. Similarly, the Lyn A splice form (56 kDa), though reduced in 
expression, was also more highly phosphorylated on this residue in the MYL-R cells 
(Fig. 4.5.1A). Loss of the inactivating Y507 phosphorylation was observed only for 
Lyn B, suggesting the elevated activity state of this kinase in MYL-R cells. 
Importantly, the increase of Lyn activity was confirmed in these cells using a novel 
peptide-based fluorescent Lyn biosensor [221] (Supplemental Fig. S4.6.1).  
 Lyn hyper-activation has been attributed to imatinib resistance in MYL-R cells 
[130]. In addition, incubation of MYL-R cells with gemcitabine, Ara-C, adaphostin, or 
Immucillin H failed to activate caspase 3 in these cells, demonstrating that MYL-R 
are highly anti-apoptotic (Fig. 3.6.1 and data not shown). To investigate the 
importance of Lyn in cell survival, MYL-R cells were transfected with Lyn-directed 
siRNA or non-targeting control siRNA and then exposed to 1 µM imatinib. This 
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treatment resulted in a partial knockdown of Lyn and a significant increase in 
caspase 3 activation  (Fig. 4.5.1B-C). However, the magnitude of caspase activation 
was less than in MYL cells exposed to the same dose of imatinib (data not shown); 
this may be due to incomplete silencing of Lyn expression. In addition, pre-treatment 
with PP2, a SFK inhibitor, significantly elevated caspase activity in MYL-R cells 
treated with imatinib, an effect not observed after pre-treatment with the inactive 
inhibitor analog, PP3 (Supplemental Fig. S4.6.2). 
4.3.2. MiR181 expression is reduced in MYL-R cells 
MiRNAs are small (20-22 nt) non-coding RNA regulators of protein 
expression that have been implicated in the progression and survival of numerous 
cancers [244]. To identify miRNAs involved in anti-apoptosis, MYL and MYL-R cells 
were profiled for miRNA expression using the Human Cancer RT2 miRNA qPCR 
Array. This qRT-PCR-based assay analyzed the expression of 88 known human 
miRNAs previously associated with cancer. Duplicate experiments demonstrated 
that 15 miRNAs had a >2-fold increase in expression in MYL-R cells relative to MYL 
cells (Fig. 4.5.2A) and that 15 miRNAs showed a >2-fold decrease in relative 
expression (Fig. 4.5.2B). Importantly, we observed a strong down-regulation of the 
miR181 family (a-d) of miRNAs in MYL-R cells (Fig. 4.5.2B, C). This family of miRNA 
is highly conserved (Fig. 4.5.2D), and loss of miR181 expression is prognostic for 
aggressive AML [164, 177]. To confirm the array results, individual qRT-PCR of 
miR181b and miR181d was performed; the results of these analyses showed that 
the expression of both miRNAs was reduced approximately 10-fold in MYL-R cells 
(Supplemental Fig. S4.6.3).  
 74 
4.3.3. Lyn kinase inhibition increases miR181 expression in MYL-R cells 
To determine whether hyper-activation of Lyn regulated miR181 expression in 
MYL-R cells, cells were treated with dasatinib and miRNA expression was 
determined by qRT-PCR. As shown in Figure 4.5.3A-B, dasatinib treatment inhibited 
Lyn and increased miR181b expression in MYL-R cells in a dose-dependent 
manner. Dasatinib (1 nM) treatment produced minimal effects on cell viability (~15-
20% cell loss), as determined by MTS assay and cell proliferation (data not shown). 
The effects of Lyn inhibition on miR181b expression were confirmed by treatment 
with PP2, whereas PP3 had minimal effects on miR181b expression (Supplemental 
Fig. S4.6.4). To determine whether Lyn specifically regulated miR181b expression, 
we nucleofected MYL-R cells with Lyn-targeted siRNA. We observed a significant 
elevation in miR181b expression in comparison to control siRNA-treated cells, as 
assessed by the miR181b Taqman qRT-PCR assay and an independent qRT-PCR 
method [245] (Fig. 4.5.3C and Supplemental Fig. 4.6.5). In addition, we over-
expressed Lyn in HEK293T cells and observed a significant loss of miR181b 
expression in comparison to cells expressing the control plasmid, confirming our 
siRNA data (Supplemental Fig. S4.6.6).  
K562-R cells are a model of imatinib-resistant CML, and over-expression of 
Lyn has been attributed to the mechanism of resistance in these cells [128, 129]. To 
further determine whether Lyn regulates miR181 expression, we tested two 
independently subcloned imatinib-resistant K562-R cell lines, termed K562-R(1) and 
K562-R(2). Similar to MYL-R cells, dasatinib treatment of K562-R cells inhibited Lyn 
activity and increased miR181b expression (Fig. 4.5.3E-G). In addition, dasatinib 
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treatment increased miR181d expression in each imatinib-resistant cell line (Fig. 
4.5.3D-F). These data support our hypothesis that hyper-activation of Lyn represses 
miR181 expression in imatinib-resistant CML.  
4.3.4. Mcl-1 is a target of miR181b 
To investigate the potential significance of miR181 to cell survival, we sought 
to identify mRNA targets for miR181. Public database bioinformatic algorithms 
(www.targetscan.org) predict a binding site for miR181 on the 3’ UTR of Mcl-1, a 
Bcl-2 family member and anti-apoptotic protein (Fig. 4.5.4A) [243]. Mcl-1 expression 
inversely correlates with leukemia chemosensitivity [242], and Western blot analysis 
determined that Mcl-1 expression was higher in MYL-R cells (Fig. 4.5.4B). 
Furthermore, inhibition of Lyn with dasatinib decreased Mcl-1 expression in a dose-
dependent manner, demonstrating the importance of Lyn activity in regulating Mcl-1 
expression (Fig. 4.5.4C).  
To determine whether miR181b regulates Mcl-1 expression, MYL-R cells 
were nucleofected with a miR181b-expressing plasmid vector (SDSA-miR181b) or 
empty vector (SDSA 3.0) control. Expression of GFP confirmed nucleofection and 
plasmid processing (Fig. 4.5.5A). In addition, qRT-PCR confirmed miR181b 
expression in these experiments (data not shown). As shown in Figure 4.5.5A, over-
expression of miR181b in MYL-R cells significantly decreased Mcl-1 expression in 
comparison cells expressing the empty vector control.  
MiRNAs regulate protein expression by binding to the 3’ UTR of target mRNA 
and initiate mRNA degradation or inhibit translational processing [157]. To determine 
whether miR181-dependent inhibition of Mcl-1 expression was due to a direct 
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interaction, HEK293T cells were co-transfected with the miR181b construct or empty 
vector and a luciferase-reporter construct containing the 3’ UTR of Mcl-1 mRNA (Fig. 
4.5.5B). Using this approach, we observed that over-expression of miR181b 
significantly inhibited luciferase activity in comparison to the vector control cells (Fig. 
4.5.5C). Because the miRNA “seed region” is critical for the recognition of miRNA 
targets, complementary nucleotides within this region were mutated in the 3’ UTR of 
the Mcl-1 luciferase reporter (Fig. 4.5.5B). These mutations ablated the miR181b-
dependent repression of luciferase activity (Fig. 4.5.5C), whereas mutation of 
nucleotides outside the seed region failed to affect this process (data not shown). 
These data suggest that miR181b directly interacts with the 3’ UTR of Mcl-1 mRNA 
to inhibit Mcl-1 protein expression, and nucleotides within the seed region of this 
binding site are important to mediate this effect. 
4.3.5. Lyn kinase regulates miR181b and Mcl-1 expression in AML 
The HL-60 cell line is a commonly used cell model for the study of AML. 
Previously, it was shown that 1,25-D3 treatment increased the expression of Lyn in 
these cells [246]. To determine whether manipulation of Lyn expression in HL-60 
cells affected miR181b and Mcl-1 expression, we treated these cells with 1,25-D3 for 
up to 96 hr. A strong increase in active Lyn expression was observed by Western 
blotting these samples (Fig. 4.5.6A). In agreement with our data obtained with the 
MYL-R and K562R cells, the increase in Lyn expression correlated with repression 
of miR181b and increased Mcl-1 expression in a time-dependent manner (Fig. 
4.5.6A-B). Thus, these results indicate that Lyn can affect Mcl-1 expression through 
modulation of miR181b expression in an AML cell line. 
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4.4. Discussion 
These studies describe three important findings: one, that the hyper-activation 
of Lyn suppresses the expression of miR181; two, that miR181b represses the 
expression of a key anti-apoptotic protein, Mcl-1; and three, loss of miR181 upon 
Lyn activation may represent a novel mechanism of drug resistance in leukemia. 
This mechanism was observed in cell models of CML and AML, and the specific role 
of Lyn was confirmed by dasatinib treatment, Lyn-targeted siRNA, and over-
expression of Lyn. Considerable evidence now supports the role of Lyn as a 
“compensatory oncogene” in imatinib-resistant CML and specific subtypes of AML. 
Lyn is over-expressed in drug-resistant cell lines and patient samples [128, 129, 
131] and activated in response to Flt3 activation or Flt3-ITD mutation [152]. Using a 
model of Lyn-dependent CML, we observed strong repression of the miR181 family 
of miRNAs. Previously, low miR181 expression has been associated with poor 
prognosis in AML, whereas high miR181 (a-d) expression is prognostic for event 
free survival in AML patients [164, 176, 177]. 
 Although our studies primarily focused on miR181b, this family of miRNAs is 
highly conserved. Previous studies suggest Bcl-2 as a target for repression by 
miR181 microRNAs [173, 179]. Comparison of the potential 3’ UTR targeting 
sequence of Bcl-2 with that of Mcl-1 demonstrates a remarkable homology between 
these sequences, which includes conservation within the seed sequence. The seed 
sequence is a key region of complementary necessary for the targeting of miRNAs 
[247]. Our results demonstrated that mutation of the nucleotides complementary to 
the miR181 seed sequence in the 3’ UTR of Mcl-1 ablated the effects of miR181b. 
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Whether miR181 directly targets Bcl-2 has yet to be confirmed; however, this is 
would establish the importance of the miR181 family in the regulation of 
mitochondria-mediated apoptosis.   
Previous studies have identified multiple miRNAs that are altered in drug-
resistant cancer, suggesting that some miRNAs have tumor suppressive effects, 
whereas others mediate cell survival [248]. A recent study profiled miRNAs from 
imatinib-resistant CML patients who did not have BCR-Abl mutations [249]. These 
authors identified 19 miRNAs that were differentially expressed between drug-
resistant patients and drug-responders. In agreement with their results, we observed 
down-regulation of the expression of miR183 and two members of the Let-7 family 
(Let-7a, Let-7b). However, in contrast to studies reporting decreased miR10a 
expression in drug-resistant CML, we observed increased miR10a expression in the 
MYL-R cells. Many of the other miRNAs reported by San Jose-Eneriz et al. were 
either unchanged or not present on our arrays. 
 Previous studies have identified miRNAs that target Mcl-1 [171, 173, 174], 
and we measured the expression of these miRNAs in our cell lines; however, the 
expression of these miRNAs were not implicated in the mediation of Mcl-1 regulation 
in MYL and MYL-R cells, suggesting that they may contribute to Mcl-1 expression in 
a cell-type specific manner. In addition to the miR181 family, we observed many 
unique differences in miRNA expression between MYL and MYL-R cells (miR10a, 
miR128a, miR132, miR150, miR155, miR183, miR196a, and miR212). It is possible 
that some of these miRNAs may play a role in the mediation of drug resistance, and 
this will be a focus of future research. 
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Recently, Chen et al. demonstrated that miR181a over-expression sensitized 
cells to radiation [173]. Moreover, Studzinski and colleagues have demonstrated that 
1,25-D3 treatment of HL-60 cells not only increases Lyn expression, but also 
decreases miR181 expression and increases Mcl-1 expression [246, 250, 251]. This 
work was published independently over a course of a decade. Our study is in 
agreement with their data, and, importantly, we believe our study provides further 
mechanistic insight to these observations. Finally, Studzinski and colleagues 
determined that 1,25-D3 treatment decreases sensitivity to drugs that induce 
apoptosis [252]; this observation is in agreement with our data suggesting that Lyn-
dependent loss of miR181 may contribute to the development of  imatinib resistance. 
While the mechanism of Lyn repression of miR181 is not known, miRNA 
expression can be regulated by cell signaling events by both genetic and epigenetic 
mechanisms. For instance, the role of BCR-Abl in the silencing of miR328 in CML 
through a MAPK-dependent manner was recently shown [253]. Furthermore, 
activating mutations of the c-Kit kinase induce a MYC-dependent repression of 
miR29b in AML [254]. In addition to transcription factor (CEBPα, Myc, etc.)-
dependent mechanisms, kinases may regulate miRNA expression through post-
transcriptional events, such as that observed with Lin28 [165, 168]. Future studies 





Figure 4.5.1. Lyn kinase confers imatinib resistance in MYL-R cells. A) 2x106 
cells were lysed and Western analysis was performed using the indicated antibodies 
(pY507, inhibitory phosphorylation site; pY397, autophosphorylation site) and 
densitometry was performed. Representative data are shown. B and C) 1x106 MYL-
R cells were nucleofected with siRNA (100 nM) against Lyn or non-targeting control 
siRNA (C). B) Forty-eight hr later, cells were lysed and Western blot analysis was 
performed using the indicated antibodies and densitometry was performed. 
Representative data are shown. C) Cells were plated in a 96-well plate (6x105/well) 
and cultured with imatinib (1.0 µM) or DMSO for the indicated time. Cells were then 
lysed and caspase 3 activity was measured as described in Section 2.3.4. Caspase 







Figure 4.5.2. Loss of miR181 expression in MYL-R cells. A and B) MYL and 
MYL-R miRNA expression was determined by qRT-PCR using the Human Cancer 
RT2 miRNA qPCR Array according to the manufacturer’s instructions. The heat map 
depicts fifteen miRNAs that had a >2-fold A) increase or B) decrease in expression 
in MYL-R cells in comparison to MYL cells. Arrows denote miR181 family members. 
Data represent duplicate experiments performed with triplicate samples. C) The fold 
change in miR181 expression in MYL-R cells in comparison to MYL cells. D) 
Alignment of human miR181 miRNAs (5’->3’) using ClustalW software 




Figure 4.5.3. Lyn kinase inhibition increases miR181 expression. A and B) 
2x106 MYL-R cells were treated for 24 hr with the indicated dose of dasatinib or 
DMSO. A) Total RNA was extracted and miR181b expression was measured by 
qRT-PCR. Data represent the mean ± S.E.M. of triplicate samples. B) Cells were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. C) 1x106 MYL-R cells were nucleofected with siRNA 
against Lyn or non-targeting control siRNA. Forty-eight hr later, RNA was extracted 
and miR181b expression was determined by qRT-PCR. Data represent the mean ± 
S.E.M. of duplicate experiments performed with triplicate samples (**, p=0.0036). D-
G) 2x106 cells were treated for 24 hr with 1 nM dasatinib or DMSO. D-F) Total RNA 
was extracted from D) MYL-R, E) K562-R(1), and F) K562-R(2) cells and miRNA 
expression was measured by qRT-PCR. Data represent the mean ± S.E.M. of 
duplicate experiments performed with triplicate samples. G) 1x106 cells were lysed 
and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. 
 86 
Figure 4.5.4. Mcl-1, a predicted target of miR181, is over-expressed in MYL-R 
cells. A) Schematic depiction of the predicted miR181 binding site in the Mcl-1 3’ 
UTR (www.targetscan.org). B) 2x106 cells were lysed, and Western blot analysis 
was performed using the indicated antibodies. Samples were loaded in duplicate. 
Representative data are shown. C) 2x106 MYL-R cells were treated for 24 hr with the 
indicated dose of dasatinib or DMSO. Cells were lysed and Western blot analysis 
was performed using the indicated antibodies. Representative data are shown.
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Figure 4.5.5. MiR181b inhibits Mcl-1 expression. A) 1x106 MYL-R cells were 
nucleofected with the SDSA 3.0 miR181b vector or empty vector (SDSA 3.0). Forty-
eight hr later, cells were lysed and Western blot analysis was performed using the 
indicated antibodies. Representative data is shown. B) Schematic depiction of 
luciferase constructs containing the Mcl-1 3’ UTR. Alignment of miR181b with the 
WT and mutant Mcl-1 3’ UTR sequences. An asterisk denotes a nucleotide mutation 
in the predicted miR181b binding site. C and D) HEK293T cells (3x105) were co-
transfected with the indicated SDSA 3.0 and psicheck Mcl-1 3’ UTR vectors. Twenty-
fours hr later cells were lysed. C) Luciferase activity was measured as described in 
Section 2.3.8. Transfection and luciferase activity assay. Data represent the mean ± 
S.E.M. of duplicate experiments performed with triplicate samples (***, p<0.001). D) 
Western blot analysis was performed with the indicated antibodies. Representative 
data is shown. 
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Figure 4.5.6. Up-regulation of Lyn kinase expression in HL-60 cells decreases 
miR181b expression and increases Mcl-1 expression. A and B) 1x106 HL-60 
cells were treated with DMSO (96 hr) or 10 ng/ul 1,25-D3 for the indicated time. A) 
Cells were lysed, and Western blot analysis was performed using the indicated 
antibodies. Representative data is shown. B) Total RNA was extracted and miR181b 
expression was measured by qRT-PCR. Data represent the mean ± S.E.M. of 
triplicate samples. 
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4.6. Supplemental figures 
Supplemental Figure 4.6.1. Lyn kinase is hyper-activated in MYL-R cells. A and 
B) Cells (2x106) were lysed and 500 µg of total cell lysate was incubated with 
agarose beads conjugated to anti-Lyn antibodies or BSA at 4°C for 2 hr. Samples 
were centrifuged and the supernatant was collected. A) Supernatant (2.5 µg/µl) was 
incubated with a fluorophore-conjugated Lyn peptide sensor (Ac-E-K-E-I-Y-G-E-I-E-
A-NH2) and fluorescence was recorded on a plate reader. B) Western blot analysis 
was performed on the supernatant using the indicated antibodies. Representative 
data are shown. Adapted from [221]. 
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Supplemental Figure 4.6.2. Lyn kinase inhibition sensitizes MYL-R cells to 
imatinib treatment. A and B) MYL-R cells (2x106) were incubated with DMSO, PP2 
(5 µM), PP3 (5 µM), or imatinib or a combination thereof for 24 hr. A) Cells were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. B) Cells were lysed and caspase 3 activity was 
measured as described in Section 2.3.4. Caspase 3 activity assay. Data represent 
the mean ± S.E.M. of triplicate samples. 
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Supplemental Figure 4.6.3. Quantitative RT-PCR of miR181b and miR181d 
expression. Total RNA was extracted from 2x106 cells and miRNA expression was 
determined by qRT-PCR. Data represent the mean ± S.E.M. of triplicate 
experiments performed with triplicate samples (***, p<0.001). 
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Supplemental Figure 4.6.4. Lyn kinase inhibition increases miR181b 
expression. MYL-R (2x106) cells were treated with DMSO, PP2 (5 µM), or PP3 (5 
µM) for 24 hr. Total RNA was extracted and miR181b expression was determined by 
qRT-PCR. Data represent the mean ± S.E.M. of triplicate samples (***, p<0.001). 
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Supplemental Figure 4.6.5. Treatment with Lyn kinase-directed siRNA 
increases miR181b expression. MYL-R (1x106) cells were nucleofected with 100 
nM non-targeted control or Lyn-directed siRNA. Forty-eight hr later, total RNA was 
extracted and miR181b expression was determined by qRT-PCR using the method 
of Thomson et al. 2006. Data represent the mean ± S.E.M. of duplicate experiments 
performed with duplicate samples. 
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Supplemental Figure 4.6.6. Lyn kinase over-expression decreases miR181b 
expression. A and B) HEK293T cells (2x106) were transfected with pcDNA or Lyn-
expressing plasmids. Analysis was performed 36 hr post-transfection. A) Cells were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. B) Total RNA was extracted and miR181b 
expression was determined by qRT-PCR. Data represent the mean ± S.E.M. of 





















All figures contributed by Eric I. Zimmerman.
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5.1. Abstract 
 In Chapter 4, we describe the negative regulation of miR181 by Lyn kinase 
(Lyn). In this chapter, we attempt to determine the mechanism(s) of Lyn-dependent 
miRNA regulation. Initially, we observed that expression of the miR181b primary 
transcript was severely reduced in MYL-R cells in comparison to MYL cells. In 
addition, transcript levels were increased after Lyn inhibition, similar to the effects on 
mature miRNA expression. Thus, we hypothesized that Lyn regulates miR181 
expression at the transcriptional level. After profiling the effects of dasatinib 
treatment on kinase signaling using the Proteome Profiler Human Phospho-kinase 
Array, we determined that Lyn regulates the phosphorylation of the transcription 
factors (TFs) CREB and STAT5 in MYL-R cells. However, subsequent inhibition of 
these TFs did not affect miR181b expression. In contrast to the relatively 
uncharacterized promoter elements for miR181b, the miR181c/d promoter contains 
two CpG islands and treatment with the DNA methyltransferase inhibitor 5-aza-C 
increased miR181c/d expression. Furthermore, increased histone acetylation after 
treatment with histone deacetylase inhibitors (HDACi) or dasatinib correlated with 
enhanced miR181c expression. However, in contrast to dasatinib treatment, HDACi 
treatment also reduced the expression of Lyn, possibility due to loss of HSP90 
activity. Thus, in regard to the miR181c/d gene cluster, Lyn may regulate expression 
by affecting DNA methylation indirectly through the modification of histones. Future 




 It is speculated that microRNAs (miRNAs) impact the expression of nearly 
one-third of all protein-coding genes [255], and miR181, in particular, regulates the 
expression of oncogenes implicated in hematopoietic disorders, such as TCL-1 and 
p27 [250, 256]. Thereby, miRNAs are involved in numerous developmental and 
physiological processes. Due to the broad impact of this RNA class, it is important to 
elucidate the regulation of miRNA expression by cell signaling cascades to better 
understand human disease. In this chapter, I attempt to address a logical extension 
of the conclusions from Chapter 4: how is miR181 regulated by Lyn kinase? 
MiRNA biogenesis is regulated at both the transcriptional and post-
transcriptional levels. These non-coding RNAs are initially transcribed as primary 
transcripts (pri-miRNA), which are often thousands of nucleotides in length and 
acquire a stem-and-loop structure [157]. After processing by the RNAse Drosha into 
a shorter (100-500 nt) pre-miRNA form and subsequent export from the nucleus, the 
RNAse Dicer produces the mature species, a molecule typically 20-22 nt in length. 
MiRNA then bind, by virtue of complementary base-pairing, to mRNA and initiate 
mRNA silencing by degradation [257], deadenylation [258], or translational 
repression [259] through association with the RNA-induced silencing complex 
(RISC). 
 Many miRNAs are located within largely uncharacterized intergenic regions of 
the genome. These regions are void of genes and may span kilobases of 
nucleotides. Therefore, intergenic miRNAs are thought to be under the control of 
unique promoter elements. By contrast, miRNAs that are located within the introns of 
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existing mRNA (intronic) are thought to be regulated coordinately with transcription 
of the host mRNA; however, as recent studies have demonstrated, this assumption 
may not always be valid [260].  
 In general, miRNA transcriptional regulation remains poorly understood. Most 
pri-miRNAs are transcribed by the polymerase II (Pol II) enzyme [261], whereas 
some pri-miRNAs are transcribed by Pol III [262]. However, a deficit in promoter 
sequence characterization and annotation of transcriptional start sites (TSSs) is a 
major limitation to understanding what additional factors regulate miRNA 
transcription. The observation that certain histone modifications (H3K4me3, H3K9 
Ac) are associated with transcriptionally active promoters [263] and that nucleosome 
activity is depleted within 100-130 base-pairs of the TSS [264] have resulted in 
efforts to map miRNA promoter signatures [260, 265]. Future studies to discover 
miRNA promoter elements may be benefited by systems biologic and bioinformatic 
analyses. 
 The miR181 family of miRNAs consists of four members (miR181a-d). 
MiR181a is clustered with miR181b and miR181c is clustered with miR181d, 
suggesting that these miR181 pairs are coordinately regulated (miRBase; 
www.mirbase.org). In addition, the miR181a/b cluster is found at two genomic 
locations (1;q32.1 and 9;q33.3), whereas the miR181c/d cluster is located on 
chromosome 19 (19; p13.1). Each cluster is within an intergenic region and no family 
member is associated with a known gene. Additionally, the promoter regions and 
regulation of miR181 by transcriptional elements are largely undefined. 
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 In this chapter, we took a logical approach to identify the mechanism(s) of Lyn 
kinase (Lyn)-dependent miR181 regulation. We initially focused on key transcription 
factors (TFs) responsive to Lyn inhibition and tested whether they could affect 
miR181b expression. Our findings argue against the regulation of miR181b by the 
TFs cAMP response element binding protein (CREB) and signal transducer and 
activator of transcription 5 (STAT5). Because previous studies suggest that the 
miR181c/d cluster is epigenetically regulated, we determined whether methylation 
and/or acetylation could explain the Lyn-dependent effects on miR181c/d expression 
[266, 267]. Our studies confirmed that the miR181c/d cluster is regulated by 
methylation in MYL-R cells. Interestingly, we found that treatment with the Src family 
kinase (SFK) inhibitor dasatinib enhanced histone acetylation and methylation, 
resulting in increased miR181c/d expression, presumably through a loss of DNA 
methylation. Furthermore, Lyn over-expression decreased histone acetylation, 
confirming the link between Lyn activity and the regulation of gene expression. 
These effects were similar to that of histone deacetylase inhibitor (HDACi) treatment; 
however, HDACi treatment also decreased HSP90 activity, subsequently reducing 
Lyn expression. Thus, HDACis may affect miR181c/d expression through both 
genomic and non-genomic mechanisms. 
5.3. Results 
5.3.1. Lyn kinase inhibition decreases the phosphorylation of CREB and 
STAT5 
 To determine the molecular consequences of Lyn inhibition, we treated MYL-
R cells with the SFK inhibitor dasatinib and analyzed the activity of multiple kinase 
 100 
signaling pathways using the Proteome Profiler Human Phospho-kinase Array. 
Treatment with 10 nM dasatinib for 24 hr resulted in specific changes in kinase 
activity. Among the SFKs measured on the array, we detected a loss of both Lyn 
(Y397) and Yes (Y426) phosphorylation, whereas, surprisingly, an increase in Fyn 
(Y420) phosphorylation was observed (Fig. 5.5.1A-B). In addition, Chk-2 (T68) 
phosphorylation was increased and phosphorylation of the TFs CREB  (S133) and 
STAT5a/b (Y699) was decreased (Fig. 5.5.1A-B). Dose-dependent confirmation of 
the loss of CREB and STAT5 phosphorylation was obtained by Western blot 
analysis (Fig. 5.5.1C). Interestingly, dasatinib not only reduced STAT5 
phosphorylation, but also decreased STAT5 expression (Fig. 5.5.1C).  
Studies in our lab have shown that dasatinib-induced Chk-2 phosphorylation 
in MYL-R cells is due to activation of ataxia telangiectasia mutated (ATM) kinase 
(data not shown), probably as a result of a general stress response. Therefore, we 
focused on the relationship between Lyn and CREB and STAT5 activity. In this 
regard, analysis of the phosphorylation of CREB (S133) and STAT5 (Y694) between 
MYL-R cells and low Lyn-expressing MYL cells demonstrated that CREB and 
STAT5 phosphorylation corresponded with Lyn expression and activity (Fig. 5.5.1D).  
5.3.2. Pri-miR181b expression is regulated by Lyn kinase 
 In Chapter 4, we describe that inhibition of Lyn rescues mature miR181 
expression. To determine whether Lyn regulates miR181 at the transcriptional level, 
we measured the expression of pri-miR181b using non-quantitative RT-PCR. 
Primers were designed against both the pri-miR181b-1 (Chr 1;q32.1) and pri-
miR181b-2 (Chr 9;q33.3) transcripts. Initially, we profiled primary transcript 
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expression in MYL and MYL-R cells and found a profound loss of both miR181b-1 
and miR181b-2 in the MYL-R cells (Fig. 5.5.2A-B). To test whether loss of primary 
transcript expression was due to enhanced Lyn activity, we treated MYL-R cells with 
dasatinib and observed a dose-dependent increase in pri-miR181b-2 expression 
(Fig. 5.5.2C-D). Though we cannot rule out the possible effects of Lyn on post-
transcriptional miRNA regulation, the primary transcript data suggest that Lyn 
strongly affects miR181 transcription. 
5.3.3. CREB and STAT5 do not regulate miR181b expression in MYL-R cells 
 We tested whether the TFs CREB and STAT5, which are responsive to Lyn 
activity, could regulate miR181 expression. CREB is phosphorylated and activated 
by several signaling pathways in myeloid cells; SFKs [268], cAMP-dependent protein 
kinase (PKA) [269], protein kinase C (PKC) [270], and the mitogen-activated kinase 
(MAPK) MEK [271] directly or indirectly increase CREB S133 phosphorylation, 
leading to TF activation. However, the pathway(s) responsible for CREB activation in 
MYL-R cells is unknown. Therefore, we measured CREB phosphorylation after 
treatment with the inhibitors Go6983 (PKC; 5 µM), H89 (PKA; 10 µM), and U0126 
(MEK; 10 µM). We found that only PKC inhibition reduced CREB phosphorylation in 
MYL-R cells and that these effects were similar to dasatinib (1 nM) treatment (Fig. 
5.5.3A). However, in contrast to dasatinib treatment, PKC inhibition did not affect the 
expression of miR181b at the time points tested, suggesting that CREB does not 
regulate miR181 transcription in response to Lyn activation (Fig. 5.5.3B).  
 STAT5 promotes myelogenous leukemia cell survival and malignancy and is 
a substrate of multiple tyrosine kinases, including Lyn [272]. Because dasatinib 
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treatment reduces the phosphorylation of STAT5 in MYL-R cells, we tested whether 
inhibition of STAT5 affected miR181 expression. We treated MYL-R cells with siRNA 
directed against STAT5 and measured mature miR181b expression using qRT-PCR. 
Though a profound (60-70%) and sustained knockdown of STAT5 was achieved, 
loss of STAT5 minimally affected miR181b expression (Fig. 5.5.3C-D), suggesting 
that STAT5 is not involved in Lyn-dependent miR181 regulation. In summary, though 
Lyn (and PKC)-dependent activation of CREB and Lyn-dependent activation of 
STAT5 is up-regulated in MYL-R drug-resistant cells, these signaling pathways may 
have consequences other than the regulation of miR181b expression. 
5.3.4. MiR181c/d expression is increased after treatment with inhibitors 
against DNMT and HDAC 
 In contrast to the relatively uncharacterized promoters for the miR181a/b 
clusters, the region upstream of the miR181c/d cluster contains two CpG islands 
(Fig. 5.5.4A). A recent report by Hashimoto et al. identified the miR181c/d TSS and 
described the regulation of miR181c by methylation of the upstream CpG islands 
[267]. We found that Lyn inhibition not only increased miR181b expression, but also 
increased the expression of the miR181c and miR181d in MYL-R cells, suggesting 
that the miR181c/d cluster is under the regulation of this kinase (Fig. 5.5.4B and 
4.5.4D). Therefore, we determined whether Lyn could regulate miR181c and 
miR181d expression through epigenetic mechanisms.  
We initially determined whether the miR181c/d cluster could be regulated by 
methylation in MYL-R cells. Cells were treated with the DNA methyltransferase 
(DNMT) inhibitor 5-aza cytidine (5-aza-C) and, in both a dose- and time-dependent 
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manner, an increase in miR181c and miR181d expression was observed (Fig. 
5.5.4C-D). In agreement with Hashimoto et al., the degree of miR181c increase was 
much higher than miR181d, possibly indicating a difference in post-transcriptional 
regulation of the two miRNAs [267].  
Though these data demonstrate that miR181c/d is regulated by DNMT 
activity, the discrepancy between the effects of dasatinib and 5-aza-C at 24 hr (Fig. 
5.5.4B vs. Fig. 5.5.4D) suggests that Lyn does not affect miR181 expression through 
regulation of DNMTs. This is reinforced by the fact that DNMT activity is replication-
dependent and the cell must go through several rounds of replication for 5-aza-C to 
be functional. However, MYL-R doubling time requires approximately 22-24 hours 
(unpublished observations). Therefore, the effects of 5-aza-C on miR181c/d 
expression are minimal. Thus, Lyn may affect DNA methylation, and thereby 
miR181c/d expression, through a mechanism not involving DNMTs. 
Several studies have described active demethylation of DNA after treatment 
with HDAC inhibitors (HDACi) [273-275]. This mechanism is replication-independent 
and does not depend on the activity of DNMTs; it is thought that active 
demethylation involves the recruitment of active demethylases, such as MBD2, after 
hyper-acetylation of histones, which subsequently leads to an increase in gene 
expression [273]. Therefore, we determined the effects of HDACi treatment on 
miR181c expression. Treatment with the HDACi trichostatin A (TSA) increased 
acetylation of histone H3 in a dose-dependent manner (Fig. 5.5.4E) with a moderate 
increase in miR181c expression (Fig. 5.5.4F). Though DNA methylation was not 
measured directly, we observed a concomitant increase in histone H3K4 
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dimethylation (H3K4me2), a marker of DNA hypo-methylation (Fig. 5.5.4E) [276]. 
Thus, these data demonstrate that HDACi treatment increases miR181c expression, 
possibly through active demethylation of the promoter region.  
5.3.5. Lyn kinase regulates histone acetylation and methylation 
 As a logical extension of the HDACi data, we tested whether inhibition of Lyn 
affected histone modification. Similar to HDACi treatment, dasatinib treatment 
increased histone H4 acetylation and these effects corresponded with an increase in 
miR181c expression (Fig. 5.5.5A-B). To more thoroughly profile the effects of 
dasatinib on histone modification, we treated cells with various concentrations of 
dasatinib and Western blotted for histone acetylation and methylation. As shown in 
Figure 5.5.5C, dasatinib dose-dependently increased the acetylation of histones H4 
and H3. In addition, dasatinib treatment increased H3K4 dimethylation (Fig. 5.5.5C). 
Finally, over-expression of Lyn reduced histone H4 acetylation in HEK293 cells, 
indicating that the effects on histone modification are due to Lyn activity, specifically 
(Fig. 5.5.5D). In summary, these data suggest that Lyn regulates histone acetylation 
and methylation, which, in turn, may affect the expression of genes, such as the 
miR181c/d cluster.  
5.3.6. HDAC inhibition decreases Lyn kinase expression and activity 
 As a control experiment, we determined whether HDACi treatment could 
affect Lyn signaling. To our surprise, we found that TSA dose-dependently 
decreased Lyn phosphorylation and expression (Fig. 5.5.6A). Since previous studies 
reported that acetylation of HSP90 decreases activity, resulting in the reduced 
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stability of HSP90 client proteins [277], we tested whether HDACi treatment affected 
HSP90 activity.  
SNX5422 is a potent HSP90 inhibitor that binds to the active conformation of 
HSP90 [278]. Therefore, SNX5422-conjugated beads could be used to determine 
the amount of HSP90 activity. To test the ability of SNX5422 to recognize active 
HSP90, we treated cells with the HSP90 inhibitor 17-AAG and then incubated cell 
lysate with the SNX5422 beads. A dose-dependent reduction of HSP90 precipitation 
was observed, indicating a loss of HSP90 activity due to 17-AAG treatment (Fig. 
S5.6.1). HSP90 expression remained constant in the non-precipitated samples, 
demonstrating that 17-AAG treatment did not decrease protein stability (Fig. S5.6.1). 
SNX5422 beads were then incubated with TSA-treated MYL-R cell lysate. As 
expected, we observed a moderate dose-dependent reduction in HSP90 
precipitation after TSA treatment, indicating a loss of HSP90 activity (Fig 5.5.6B). 
Thus, the effects of HDACi treatment on Lyn activity and protein expression may be 
due to inhibition of HSP90 activity. 
5.4. Discussion 
 In this chapter, I attempted to determine the mechanism(s) of miR181 
regulation by Lyn. From our studies, the following key observations were made: 1) 
Lyn regulates miR181b expression at the transcriptional level; 2) miR181b is not 
regulated by the TFs CREB and STAT5; 3) Lyn regulates histone acetylation and 
methylation, which may affect miR181c and miR181d expression; and 4) the 
mechanism of miR181c/d regulation by HDACi may involve both an increase in 
histone acetylation and a loss of Lyn signaling. Though the exact nature of miR181 
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regulation was not fully elucidated, these results provide a foundation for future 
experiments and insight into Lyn function in drug-resistant CML. 
 Figure 1 demonstrates that MYL-R cells are not only deficient in mature 
miR181b expression, but also exhibit a loss of pri-miR181b. Furthermore, dasatinib 
treatment increases the amount of pri-miR181b expression. The increase in pri-
miR181b was approximately 3-fold at the highest dose of dasatinib tested; this is in 
contrast to an approximate 12-fold increase in mature miRNA expression (Fig. 
5.5.2C-D vs. 4.4.5A). Only one miR181b transcript (pri-miR181b-2) was measured, 
so a coordinate increase in pri-miR181b-1 may explain the apparent discrepancy 
between primary transcript and mature miR181 levels. In addition, post-
transcriptional regulation of miR181b may amplify mature miRNA expression. For 
instance, RNA-binding proteins have been found to regulate miRNA processing in a 
miRNA-specific manner. Lin-28 directly bindings let-7 miRNA [165] and regulates let-
7 maturation by inhibiting pri-miRNA and pre-miRNA cleavage by Drosha and Dicer, 
respectively [166, 279]. Other RNA-binding proteins, such as hnRNP A1, can 
enhance miRNA processing by inducing a conformational change preferred by these 
nucleases [280]. The post-transcriptional regulation of miR181 is unknown and 
future studies should determine whether miR181 undergoes alternative processing. 
 Nevertheless, the profound loss of pri-miR181b in MYL-R cells suggests that 
transcriptional regulation is the predominant mechanism of miR181b regulation in 
these cells. Furthermore, we show that the loss of activity of the TFs CREB and 
STAT5 are consequences of dasatinib treatment. Both TFs have been previously 
implicated in myeloid disorders; CREB is often over-expressed in acute 
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myelogenous leukemia (AML) and mediates growth factor-independent survival and 
proliferation of cells [281, 282], whereas STAT5 is a substrate of multiple 
hematopoietic kinase oncogenes (i.e. Lyn, BCR-Abl, and JAK) and is often 
associated with imatinib-resistant CML [283]. Due to the lack of miR181a/b promoter 
characterization we could not determine the presence of predicted STAT or CREB 
binding sites upstream of the miRNA sequences. Regardless, we tested whether 
down-regulation of these TFs affected miR181b expression. 
 Of the signaling pathways known to phosphorylate and activate CREB, only 
PKC and Lyn were found to regulate CREB phosphorylation in MYL-R cells. 
Therefore, we treated with selective inhibitors of these pathways and measured 
miRNA expression. In contrast to dasatinib treatment, treatment with the broad 
spectrum PKC inhibitor Go6983 did not affect miRNA expression at the time points 
tested. Thus, though PKC signaling is affected by Lyn inhibition, it is not involved in 
miR181b regulation. 
 We tested whether STAT5 could regulate miR181 expression by treating 
MYL-R cells with STAT5-directed siRNA. Though an efficient and sustained 
knockdown of STAT5 expression was obtained, this did not affect miR181b 
expression. While it is possible that the residual STAT5 still active during siRNA 
treatment maintained miRNA repression, our initial results suggest that this TF is not 
involved in miR181 regulation. Admittedly, a more comprehensive approach to 
determine the affects of Lyn inhibition on TF activity and signaling pathways is better 
suited to determine the mechanism of miR181 regulation; alternative approaches are 
described in more detail in Chapter 6.  
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 In contrast to the miR181a/b clusters, the TSS is known for the miR181c/d 
cluster. Furthermore, it has been shown that these miRNAs are epigenetically 
regulated due to the presence of conserved CpG islands within the promoter region. 
Hashimoto et al. found that 5-aza-C treatment of gastric cancer cell lines decreased 
DNA methylation within the CpG islands and increased the expression of miR181c 
and miR181d [267]. We replicated these results in the MYL-R cells. Thus, these data 
suggest that Lyn may regulate miR181 expression by affecting DNA methylation 
status. However, the time course of the effects of DNMT inhibition on miR181 
expression did not match the time course of dasatinib-mediated effects (Fig. 5.5.4B 
vs. 5.5.4D). Multiple cell replications are necessary for DNMT-mediated transfer of 
epigenetic information and for 5-aza-C-mediated inhibition of DNMTs; however, 
apparently, cell replication is not necessary for Lyn-mediated affects on miR181 
expression because the MYL-R doubling time is approximately 22-24 hours. 
Therefore, we tested whether active demethylation could affect miR181c expression. 
 Replication-independent active demethylation occurs upon epigenetic 
modification of histones. Specifically, an increase in histone acetylation decreases 
heterochromatin formation, exposing DNA to demethylating enzymes, such as 
MBD2, and results in an increase in gene transcription [284]. Thus, numerous 
reports have shown that HDACi treatment increases gene transcription, at least in 
part, through DNA demethylation, molecular justification for the combined use of 
HDAC inhibitors and DNMT inhibitors for cancer therapy [285]. Furthermore, a study 
by Fayyad-Kazan et al. showed that treatment with the HDACi VPA resulted in an 
increase in miR181c expression in CD4+ T-cells [266]. Indeed, in the MYL-R cells 
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both VPA and TSA treatment resulted in an increase in miR181c expression. To 
determine whether this resulted in changes in methylation, we measured the 
dimethylation of histone H3 at lysine 4 (K4), a marker of DNA hypo-methylation and 
gene transcription [276]. As predicted, inhibition of HDACs increased methylation, 
suggesting that Lyn may alter histone modification to indirectly affect miR181c/d 
cluster expression. 
 To further test this hypothesis, we determined the effects of Lyn inhibition on 
histone modification. Importantly, we showed that dasatinib treatment increased 
histone acetylation, as measured by histone H4 and H3 acetylation. Furthermore, 
histone methylation was increased, recapitulating the results of HDACi treatment. 
Finally, Lyn over-expression resulted in a loss of histone H4 acetylation.  
Lyn regulation of histone modification has broad implications and may provide 
a mechanism for not only miR181c/d regulation, but also the regulation of multiple 
other genes shown to be epigenetically sensitive. Whether Lyn promotes histone 
acetylation through inhibition of HDAC function is an important question for future 
studies. HDAC1 is phosphorylated on tyrosine residue 221, which is conserved in 
HDAC2 and HDAC3 (Fig. S5.6.2); however, the biological context of this event has 
not been determined [286]. In addition, it has been shown that HDAC3 co-localizes 
with Src kinase and is a substrate of this kinase [287]. Whether HDACs are directly 
phosphorylated by Lyn and whether this modification is relevant to HDAC function is 
currently being tested. 
 As a control experiment, we determined whether Lyn, itself, was affected by 
HDACi treatment. To our surprise, we found that TSA dose-dependently reduced 
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Lyn activity and expression. Though we have not measured Lyn transcription after 
HDACi treatment, previous reports have described HDACi-dependent enhancement 
of HSP90 acetylation, which reduces HSP90 activity. Acetylation-dependent loss of 
HSP90 function results in a reduction in the stability of HSP90 client proteins, such 
as BCR-Abl and c-Kit [288, 289]. This effect has been attributed to inhibition of 
HDAC6 [290], which is primarily cytoplasmic and associates with microtubules [291]. 
Because Lyn is an HSP90 client (data not shown), we hypothesized that the HDACi-
dependent loss of Lyn expression is due to a reduction in HSP90 activity. This was 
confirmed by precipitation of HSP90 with SNX5422, an HSP90 inhibitor that binds 
only active HSP90, which demonstrated that HDACi treatment dose-dependently 
decreased HSP90 activity, presumably due to increased acetylation. Therefore, the 
effects of HDACi treatment on miR181c expression may be due to both genomic and 
non-genomic mechanisms. Future studies using selective HDAC6 inhibitors, such as 
tubastatin A [292], should be performed to determine the contribution of HSP90-
dependent processes to miR181c/d cluster regulation.  
 Though this chapter does not fully elucidate the mechanism(s) of Lyn-
dependent miR181 regulation, our data shed light on some interesting aspects of 
Lyn function. Studies designed to interrogate the mechanism of dasatinib-induced 
histone acetylation and the non-genomic functions of specific HDAC isoforms will 
increase our knowledge of cellular adaptation to drug treatment and may have broad 




Figure 5.5.1. Lyn kinase inhibition decreases CREB and STAT5 activity. A) 
MYL-R cells (4x106) were treated with DMSO or 10 nM dasatinib for 24 hr. Analysis 
of protein phosphorylation was performed using the Proteome Profiler Human 
Phospho-kinase Array according to the manufacturer’s instructions. B) Densitometry 
was performed using a FluorChem FC2 imager. C) MYL-R cells (2x106) were treated 
with DMSO or dasatinib for 24 hr. Cells were lysed and Western blot analysis was 
performed using the indicated antibodies. Representative data are shown. D) Cells 
(2x106) were lysed and Western blot analysis was performed using the indicated 
antibodies. Representative data are shown. 
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Figure 5.5.2. Regulation of pri-miR181b by Lyn kinase. A) Total RNA was 
extracted from 2x106 cells. Non-quantitative RT-PCR was performed using primers 
for pri-miR181b. Representative data are shown. B) Densitometry was performed 
using a FluorChem FC2 imager. C) MYL-R cells (2x106) were treated with DMSO or 
dasatinib for 24 hr. Total RNA was extracted and non-quantitative RT-PCR was 
performed using primers for pri-miR181b-2. Representative data are shown. D) 
Densitometry was performed using a FluorChem FC2 imager. 
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Figure 5.5.3. CREB and STAT5 do not regulate miR181b expression. A) MYL-R 
cells (4x106) were treated with DMSO, Go6983 (5 µM), H89 (10 µM), U0126 (10 
µM), or dasatinib (1 nM) for 24 hr. Cells were lysed and Western blot analysis was 
performed using the indicated antibodies. Samples were loaded in duplicate. 
Representative data are shown. B) MYL-R cells (4x106) were treated with DMSO (24 
hrs), Go6983 (5 µM) or dasatinib (1 nM) for 8, 12, and 24 hr. Total RNA was 
extracted and miR181b expression was determined by qRT-PCR. Data are 
normalized to DMSO (24 hrs) and represent the mean ± S.E.M. of triplicate samples. 
C and D) MYL-R cells (1x106) were nucleofected with 100 nM non-targeted control 
siRNA (C) or siRNA against STAT5. Analysis was performed twenty-four and forty-
eight hr later. C) Cells were lysed and Western blot analysis was performed using 
the indicated antibodies. Representative data are shown. D) Total RNA was 
extracted and miR181b expression was determined by qRT-PCR. Data represent 









Figure 5.5.4. miR181c/d expression is increased by DNMT and HDAC 
inhibition. A) Schematic depiction of the miR181c/d gene cluster (nt, nucleotide; 
TSS, transcriptional start site; pre-, pre-miRNA sequence; M, mature miRNA 
sequence). B) MYL-R cells (2x106) were treated with DMSO or 1 nM dasatinib for 24 
hr. Total RNA was extracted and miRNA expression was determined by qRT-PCR. 
Data represent the mean +/- SEM of triplicate samples. C) MYL-R (2 x 106) cells 
were treated with DMSO or 5-aza-C for 72 hrs. Total RNA was extracted and miRNA 
expression was determined by qRT-PCR. Data represent the mean ± S.E.M. of 
triplicate samples. D) MYL-R cells (2x106) were treated with DMSO (72 hr) or 5-aza-
C for 24, 48, and 72 hr. Total RNA was extracted and miRNA expression was 
determined by qRT-PCR. Data represent the mean ± S.E.M. of triplicate samples. E 
and F) MYL-R cells (4x106) were treated with DMSO or TSA for 24 hr. E) Cells were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. F) Total RNA was extracted and miR181c 
expression was determined by qRT-PCR. Data represent the mean ± S.E.M. of 
triplicate samples. 
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Figure 5.5.5. Lyn kinase regulates histone post-translational modification. A 
and B) MYL-R cells (4x106) were treated with DMSO, VPA (1 mM), TSA (300 nM), or 
dasatinib (1 nM) for 6 hr or as indicated. A) Cells were lysed and Western blot 
analysis was performed using the indicated antibodies. Representative data are 
shown. F) Total RNA was extracted and miR181c expression was determined by 
qRT-PCR. Data represent the mean ± S.E.M. of triplicate samples. C) MYL-R cells 
(2x106) were treated with DMSO or dasatinib for 24 hr. Cells were lysed and 
Western blot analysis was performed using the indicated antibodies. Samples were 
loaded in duplicate. Representative data are shown. D) HEK293T cells (2x106) were 
transfected with pcDNA or Lyn-expressing plasmids. Thirty-six hr later cells were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. 
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Figure 5.5.6. HDAC inhibition decreases HSP90 activity and Lyn kinase 
expression. A and B) MYL-R cells (2x106) were treated with DMSO or TSA for 24 hr 
and lysed. A) Western blot analysis was performed using the indicated antibodies. 
B) Lysate was incubated with SNX5422-conjugated beads for 2 hr at 4°C. Western 
blot analysis was performed on the eluent and 10% of the lysate input using the 
indicated antibodies. Representative data are shown. 
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5.6. Supplemental figures 
 
Supplemental Figure 5.6.1. SNX5422-conjugated beads precipitate active 
HSP90. MYL-R cells (2x106) were treated with DMSO or 17-AAG for 24 hr. 250 µg 
of total cell lysate was incubated with SNX5422-conjugated beads for 2 hr at 4°C in 
a total volume of 200 µl. Afterward, beads were washes 3 times with RIPA buffer (no 
SDS) and protein was eluted using 1X sample buffer. Western blot analysis was 
performed on the eluent and 25 µg of lysate for each sample using the indicated 
antibodies. Representative data are shown. 
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Supplemental Figure 5.6.2. Sequence alignment of human HDAC1-3. Alignment 
of amino acids 216-231 of human HDAC1 with HDAC2 and HDAC3 using ClustalW 
software (http://align.genome.jp/). An asterisk denotes a conserved residue. An 



















All figures contributed by Eric I. Zimmerman. 
Data contributed to Fig. 6.4.1. and 6.4.2. by Brian Dewar, James Duncan, Marty 
Whittle, and Matt Cooper.
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6.1. Summary 
 My dissertation research investigated mechanisms of resistance to 
chemotherapy in cell models of leukemia. These studies initially focused on ENT1, a 
nucleoside transporter protein responsible for mediating nucleoside analog 
membrane permeability. Evidence suggests that the activity of ENTs is the limiting 
factor for nucleoside analog-induced cytotoxicity, and the expression of ENTs 
correlates with sensitivity of leukemia patients to therapy [293, 294]. Mutation, 
alternative splicing or other dysfunctions of ENT genes that affect transporter 
function may lead to drug resistance [52, 89]. For instance, Nishio et al. found that 
mislocalization of ENT2 away from the plasma membrane was responsible for 
gemcitabine resistance in pancreatic cancer cells [88]. Furthermore, cytarabine 
resistance was conferred in leukemia cell lines by a nonsense point mutation of Y11 
in ENT1, resulting in translational arrest [89].  
 In Chapter 3 I describe a mechanism by which dysfunction of ENT1 confers 
resistance to Ara-C in a cell model of T-cell acute lymphoblastic leukemia (ALL). My 
studies revealed that a single point mutation (G24R) in the TM1 portion of the 
protein disrupts ENT1 transport activity, even though the protein was properly 
localized to the plasma membrane. Previous reports have focused on the TM1 
region of this protein and discovered residues (M33, W29) important for substrate 
and inhibitor recognition [55, 56]. My data extends the findings of these studies and 
provides novel information on the determinants of ENT1 transporter activity within 
TM1. 
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 In Chapter 4 we initiated a new study that focused on kinase regulation of 
drug resistance in an imatinib-resistant cell model of chronic myelogenous leukemia 
(CML), termed MYL-R. The MYL-R cells are resistant to multiple drugs with distinct 
modes of action, including nucleoside analogs, suggesting that cell death is 
prevented at a broad, non-specific level as opposed to alteration of BCR-Abl 
signaling or changes in nucleoside transport. In agreement with these predictions, 
our initial studies eliminated the contribution of BCR-Abl up-regulation or mutation as 
well as p-glycoprotein up-regulation to the mechanism of resistance. Moreover, 
absence of dysfunctional ENT activity eliminated differential transporter function 
from the mechanism of drug resistance in these cells.  
Previous studies implicated the Lyn tyrosine kinase (Lyn) as an important 
mediator of drug resistance in MYL-R cells [130]. Thus, our study focused on Lyn-
dependent molecular signaling events. In this thesis I describe the elucidation of a 
novel signaling pathway by which Lyn activation up-regulates expression of the pro-
survival protein Mcl-1. A screen for miRNA expression demonstrated that the family 
of miR181 miRNAs was highly down-regulated in the MYL-R cells. Subsequent 
experiments determined that these miRNAs were suppressed by Lyn activity.  Based 
on the predicted miR181 binding site within the Mcl-1 3’ UTR we tested whether 
miR181 targeted Mcl-1 for degradation.  Indeed, rescue of miR181b expression in 
MYL-R cells decreased Mcl-1 expression. Finally, we determined that miR181 
targeted Mcl-1 mRNA using a luciferase reporter assay, providing molecular 
evidence for the direct interaction of these molecules. 
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 Our investigations into the effects of miR181 on Mcl-1 complement recent 
work uncovering miR181-dependent degradation of Bcl-2, a protein related to Mcl-1 
[178]. Originally described by Phil Sharp and colleagues, miR181 interacts directly 
with the Bcl-2 3’ UTR to suppress Bcl-2 expression [179]. In fact, the miR181 “seed” 
region binding site is completely conserved between Bcl-2 and Mcl-1 
(www.targetscan.org). Therefore, the miR181 family may be a master regulator of 
pro-survival Bcl-2 proteins, implicating this miRNA as a potentially important 
regulator of Bcl-2- or Mcl-1-dependent drug resistance.   
 Recent studies have shown that miR181 expression affects sensitivity to anti-
cancer therapy. Over-expression of miR181a sensitized glioma cells to radiation-
induced cell death [178] and in non-small cell lung cancer cells, miR181a over-
expression increased sensitivity to cisplatin treatment [295].  These effects were 
concomitant with increased Bax oligomerization and pro-caspase cleavage, 
indicating miR181 alteration of mitochondria-mediated apoptosis, which is in 
agreement with its ability to affect Mcl-1 and Bcl-2 expression [295].  
 Interestingly, studies suggest that the miR181 family functions both as a 
tumor suppressor and oncogene depending its cellular context. In addition to 
promoting hepatocarcinogenesis [296], these miRNAs are elevated in breast [297] 
and colon tumors [298] as well as pancreatic cancer [299]. However, miR181 acts as 
a tumor suppressor in glioblastoma [300] and aggressive CLL [301]. A major 
determinant as to whether miR181 acts as an oncogene or tumor suppressor may 
be the array of mRNAs targeted by this miRNA for degradation. To date, ten specific 
targets for miR181, including p27 and TCL-1, have been reported in various cell 
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types [250, 256]. However, potentially hundreds of more targets exist for this miRNA 
family. To better evaluate the specific role of miR181 in cancer, additional analysis of 
miR181 targets must be performed. 
 The importance of miR181 to cancer biology is apparent. Herein, I propose 
two future directions for the research described in the previous chapters. These 
proposed studies will extend our knowledge of miR181 regulation and may impact 
the development of therapies for drug-resistant leukemia patients. 
6.2. Future Direction #1: Determine the kinome response to Lyn inhibition 
 In general, the effects of molecular signaling pathways on miRNA expression 
are poorly understood. Exceptions include MAPK regulation of let-7 [302] and BCR-
Abl-dependent regulation of miR328 [253], pathways which are of high impact and 
lend insight to cancer biology. Our data suggest that Lyn regulates miR181 
transcription; however, the mechanistic details of this pathway are unknown. 
Elucidation of this process has important biological and therapeutic ramifications. 
 As outlined in Chapter 5, we attempted to understand the transcriptional 
regulation of the miR181a/b and miR181c/d gene clusters. Though we determined 
that miR181c/d is epigenetically regulated in MYL-R cells, the substrates of Lyn and 
the cellular machinery necessary for miR181 expression control were not identified. 
Our initial attempt to determine Lyn-dependent signaling targets using the Phospho-
Kinase Array was unsuccessful. Therefore, to better accomplish this goal, an 
objective and more comprehensive approach to identify the molecular 
consequences of Lyn inhibition is needed. 
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 As an alternative and novel strategy I propose to determine changes in kinase 
expression and activity using affinity purification and mass spectrometry. To enrich 
for kinases, we will incubate cell lysate with beads covalently conjugated to non-
selective pan-kinase inhibitors, termed kinase inhibitor beads (KIBs) or KinoBeadsTM 
(Cellzome, Heidelberg, Germany) (Fig. 6.4.1A). Bound kinases will be eluted, tryptic 
digested and the peptides labeled using isobaric molecular tags (iTRAQ; Applied 
Biosystems) for quantitative mass spectrometry. After separation of peptides by 
reversed phase HPLC, identification and quantification of kinases will be performed 
by MALDI-TOF/TOF mass spectrometry equipped with ProteinPilot software. This 
method will be used to 1) compare kinase expression between MYL and MYL-R 
cells and 2) determine changes in kinase expression in MYL-R cells after dasatinib 
treatment and/or Lyn-directed siRNA treatment. 
 The KinoBeadTM technology was originally described by several German 
research groups, including Henrik Daub, Mathias Mann and colleagues, and has 
been implemented in cell systems for the study of kinase networks [303]. These 
beads are conjugated to pan kinase inhibitors that target the ATP-binding pocket 
and interact with multiple protein kinases primarily based on 1) kinase affinity, 2) 
kinase avidity (combined strength of multiple bonds), and 3) kinase expression. In 
addition, we have observed activity-dependent capture of kinases after treatment 
with pervanadate, an irreversible protein phosphatase inhibitor (data not shown). 
This may be due to increased affinity/avidity of activated kinases and studies are 
now being performed to profile kinase activation-loop phosphorylation using KIB 
technology. Furthermore, kinases that indirectly interact with the KIBs may be 
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precipitated as well as ATP-binding non-kinase proteins (i.e. metabolic enzymes). 
Therefore, KIB technology may be used to study protein complex formation; 
however, the isolation of proteins that interact indirectly with bead is largely affected 
by the stringency of bead washes (i.e. salt content) prior to analysis.  
 With regard to kinase network profiling, KinoBeadTM technology has 
successfully been used to determine global kinase expression in cancer cell lines 
[303] and primary cancer cells [304]. In addition, this quantitative proteomic 
approach has been useful to interrogate changes in kinase signaling during the cell 
cycle [305]. Furthermore, Bantscheff et al. used KinoBeadsTM to identify kinase 
inhibitor targets by competitive binding [306]. In this study, kinases were captured by 
KinoBeadsTM in the presence of different concentrations of BCR-Abl kinase inhibitors 
(imatinib, dasatinib, and bosutinib). The loss of peptide signal from the KinoBeadTM 
purification indicated competitive binding with the free inhibitor and identified novel 
inhibitor targets, such as the tyrosine kinase DDR1, that may be important for the 
therapeutic effects of the drug [306]. Recently, this approach was extended to 
determine the effect of kinase inhibitors on kinase phosphorylation [307]. 
Our initial studies compared kinase expression in MYL and MYL-R cells using 
KIB-mediated kinase enrichment followed by iTRAQ labeling and MALDI TOF/TOF 
analysis (Fig. 6.4.1A). Using beads conjugated to two pan-kinase inhibitors (PP58, 
VI16932) we identified approximately 120 unique kinases (Fig. 6.4.1B-C). The 
enrichment of kinases from multiple different sub-families was observed, 
demonstrating the relative lack of experimental bias of this technology (Fig. 6.4.1B). 
The inclusion of KIBs containing other pan-kinase inhibitors should increase the 
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number of kinases captured in future experiments. Interestingly, in our initial study, 
more kinases were down-regulated >2-fold than up-regulated >2-fold in MYL-R cells 
(12.8% vs. 8.5%), whereas expression of the majority of kinases was unchanged  
(78.7%) (Fig. 6.4.1C). As confirmation of our previous Western blot data, Lyn was 
found to be highly up-regulated in MYL-R cells (Fig. 6.4.2A). 
Subsequent Western blot analysis confirmed important changes in kinase 
expression between the MYL and MYL-R cells. Of note, the expression of BCR-Abl 
and c-Kit was highly down-regulated in MYL-R cells (Fig. 6.4.2A-B). These are two 
imatinib targets and the loss of expression may indicate “oncogene switching” away 
from these pro-survival kinases. In addition, Western blot analysis of IKKα and 
MEK2, two kinases up-regulated in MYL-R cells as determined by the KIB 
experiment, revealed that the expression of total protein was similar between the two 
cell lines (Fig. 6.4.2A, C). Analysis of the phosphorylated, active form of the kinases 
indicated that both were increased in activity in MYL-R, indicating that the KIBs may 
precipitate these kinases in an activity-dependent manner (Fig. 6.4.2C). In summary, 
this approach provides a robust and large-scale evaluation of kinase expression in 
leukemia cells and may give insight into kinase activity. Moreover, the finite number 
of kinases that were different between MYL and MYL-R suggests that these 
individual kinases could be targeted and evaluated for their specific effects on 
miR181 expression.  
 In the proposed experiment, identification of differentially bound kinases after 
dasatinib treatment will be followed by Western blot analysis of kinase expression 
and activity. Confirmation of dose-dependent dasatinib effects on the target kinase 
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will be followed by evaluation of Lyn involvement using Lyn-directed siRNA. Finally, 
determination of the effects of target kinase inhibition (by siRNA or selective kinase 
inhibitors) on miR181 expression will be performed. It is anticipated that this “top-
down” approach will identify Lyn-dependent kinases signaling pathways and the 
transcriptional machinery that regulates miRNA expression. 
6.3. Future Direction #2: Define miR181 regulation in AML 
As opposed to CML, AML is a much more molecularly heterogenous disease. 
Approximately 30% of patients have constitutive activation of the receptor tyrosine 
kinase, Fms-like tyrosine kinase 3 (FLT3) [308], whereas other patients express JAK 
mutations, transcription factor fusions, etc. An internal domain duplication (FLT3-
ITD) or a point mutation within the kinase domain (D835) results in ligand-
independent and IL-3 independent FLT3-ITD signaling [309-311]. The majority of 
patients with this molecular phenotype have a very aggressive disease 
characterized by a low complete remission rate and are more likely to undergo 
relapse [33, 312].  
Unlike wild-type FLT3, mutant FLT3 activates multiple pro-survival signaling 
pathways, including STAT5 [313]. In addition, a study by Okomoto et al. found that 
FLT3, in particular FLT3-ITD, associates with and activates Lyn [152]. Inhibition of 
Lyn using siRNA or the SFK inhibitor PP2, decreased STAT5 phosphorylation and 
FLT3-ITD-expressing 32D cell viability. Treatment of mice implanted with FLT3-ITD-
expressing 32D cells with PP2 decreased tumor size [152]. These data suggest that 
Lyn is an integral component of FLT3-ITD signaling and the observation that SFKs 
are activated by FLT3 and are important to AML cell survival has been confirmed by 
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independent research groups [151, 314]. Furthermore, a recent study demonstrated 
that the SFK inhibitor dasatinib is effective against molecularly heterogenous AML, 
though this compound may also inhibit FLT3 directly [315]. 
As explained above, low miR181 expression is prognostic for aggressive 
AML. A series of studies by Bloomfield and colleagues demonstrate that AML 
patients with relatively low expression of miR181 experience lower complete 
remission rates, shorter overall survival, and shorter disease-free survival in 
comparison with patients with high miR181 expression [164, 176, 177]. In both 
studies these correlations were more significant for patients characterized by FLT3-
ITD and/or NPM1 wild-type. 
Based on these studies we hypothesize that FLT3-ITD may decrease miR181 
expression through the activation of Lyn. In support of this hypothesis, preliminary 
experiments demonstrate that when FLT3-ITD-expressing MV4-11 cells are treated 
with the FLT3 inhibitors PKC412 and sorafenib, miR181b expression is increased in 
a dose-dependent manner (Fig. 6.4.3A-B). Future experiments should determine 
whether this effect is dependent on Lyn inhibition. These studies will help 
substantiate the role of SFKs in AML and will provide insight into miR181 regulation 
in the context of this deadly disease. 
6.4. Conclusions 
 In this dissertation, I have elucidated the molecular machinery, at least in part, 
responsible for drug resistance in several models of drug-resistant leukemia. I 
initially describe the importance of ENT function for nucleoside analog treatment; 
however, the primary focus of my work has been adaptation of kinase signaling to 
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drug treatment. In this regard, identification of Lyn kinase-dependent regulation of 
miR181 miRNAs and Mcl-1 expression contributes to our knowledge of imatinib 
resistance, as well as CML and AML biology. Further study of the molecular 





6.5.1. Analysis of kinase expression in MYL and MYL-R cells. A) Schematic 
depiction of mass spectrometry-based analysis of kinase expression using KIB 
technology. B) Kinase family tree depicting the expression of kinases in MYL and 
MYL-R cells (adapted from [93]). C) Percentage of kinases whose expression was 
>2-fold increased, >2-fold decreased, and unchanged (<2-fold) in MYL-R cells 
compared to MYL cells. Dotted lines indicate a 2-fold difference in expression.
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6.5.2. Confirmation of kinase expression in MYL and MYL-R cells. A) The 
expression of kinases in MYL-R cells in comparison to MYL cells. An asterisk 
denotes a kinase selected for Western blot analysis. B and C) Cells (2 x 106) were 
lysed and Western blot analysis was performed using the indicated antibodies. 
Representative data are shown. 
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6.4.3. FLT3-ITD inhibition increases miR181b expression. A and B) MV4-11 cells 
(4x106) were treated with DMSO, PKC412, or sorafenib for 24 hr. A) Total RNA was 
extracted and miR181b expression was determined by qRT-PCR. Data represent 
the mean ± S.E.M. of triplicate samples (*, p<0.05; **, p<0.01; ***, p<0.001). B) Cells 
were lysed and Western blot analysis was performed using the indicated antibodies. 
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